The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase by Guzzo, Giulia
  
 
 
 
 
                                        Sede Amministrativa: Università degli Studi di Padova 
 
                                                                Dipartimento di Biologia 
 
 
 
 
SCUOLA DI DOTTORATO DI RICERCA IN : BIOSCIENZE E BIOTECNOLOGIE 
INDIRIZZO: BIOLOGIA CELLULARE 
CICLO: XXV 
 
 
The mitochondrial chaperone TRAP1 promotes neoplastic 
growth by inhibiting succinate dehydrogenase 
 
 
 
 
Direttore della Scuola: Ch.mo Prof. Giuseppe Zanotti 
Coordinatore d’indirizzo: Ch.mo Prof. Paolo Bernardi 
Supervisore: Dr. Andrea Rasola 
Co-supervisore: Ch.mo Prof. Paolo Bernardi 
 
 
 
        
Dottorando : GIULIA GUZZO 
          
 
 
 
 
                                                                           Dicembre 2012 
1 
 
Index 
 
Index                                                                                                                       1 
Summary 3 
1.Introduction 5 
1.1 Hallmarks of cancer 5 
1.1.1 Cell sufficiency in growth signals 5 
1.1.2 Insensitivity to growth inhibitory signals 6 
1.1.3 Evasion of programmed cell death (Apoptosis) 7 
1.1.4 Limitless replicative potential 7 
1.1.5 Sustained angiogenesis 8 
1.1.6 Tissue invasion and metastasis 9 
1.1.7 Enabling Characteristic: Tumor promoting inflammation 12 
1.1.8 Enabling Characteristic: Genome instability and mutations 14 
1.1.9 Emerging Hallmark: Evading immune destruction 14 
1.1.10 Emerging Hallmark: Reprogramming energy metabolism  15 
1.2 Metabolic Alterations in cancer 15 
1.2.1 The pentose phosphate pathway 17 
1.2.2 Fatty acid synthesis 17 
1.2.3 Glutaminolysis 17 
1.3 Mitochondria and tumor 18 
1.4 Hypoxia inducible factors and cancer 20 
1.5 Chaperones in cancer 23 
2 Matherials and methods 28 
3 Results 36 
4. Discussion 62 
5 References 64 
 
 3 
 
Summary 
Cancer is a highly heterogeneous and complex disease, whose development requires a 
reorganization of cell metabolism. Most tumor cells downregulate mitochondrial oxidative 
phosphorylation and increase the rate of glucose consumption and lactate release, independently of 
oxygen availability (the Warburg effect). This metabolic rewiring is believed to favour tumor 
growth and survival. However the molecular mechanisms that inhibit oxidative phosphorylation 
(OXPHOS) during neoplastic progression are only partially understood. 
Within this context, we studied TRAP1, a conserved chaperone of the Heat Shock Protein 90 
(HSP90) family, localized mainly in the mitochondrial matrix and whose expression is induced in 
the majority of tumor types.  
We found that TRAP1 is associated to succinate dehydrogenase (SDH), the Complex II of the 
respiratory chain. We observed in different tumor cell models that TRAP1 diminished in vivo tumor 
cell respiration by inhibiting the succinate:coenzyme Q reductase (SQR) activity of Complex II. 
This Complex II inhibition was further enhanced in TRAP1-expressing cells that progressed 
through a focus forming assay (in vitro tumorigenesis assay), causing an accumulation of succinate 
that led to the stabilization of the pro-neoplastic transcription factor HIF1α,  thus favouring the 
metabolic switch necessary for tumor growth and progression. In fact, we observe in vitro e in vivo 
tumorigenesis only in TRAP1 expressing cells. 
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Riassunto 
Il cancro è una malattia altamente complessa ed eterogenea, il cui sviluppo richiede una 
riorganizzazione del metabolismo cellulare. La maggior parte delle cellule tumorali diminuisce la 
fosforilazione ossidativa mitocondriale e aumenta invece la quantità di glucosio consumato e di 
produzione di lattato, in maniera completamente indipendente dalla disponibilità di ossigeno. 
Questo fenomeno è noto come Effetto Warburg. Si pensa che questa riprogrammazione metabolica 
favorisca la crescita e la sopravvivenza del tumore. Comunque sono solo parzialmente noti i 
meccanismi molecolari che inibiscono la fosforilazione ossidativa (OXPHOS) durante la 
trasformazione neoplastica. 
In questo contesto, abbiamo deciso di studiare TRAP1, uno sciaperone appartenente alla famiglia 
delle Heat Shock Protein 90 (HSP90), che si trova principalmente nella matrice mitocondriale e la 
cui espressione è indotta nella maggior parte dei tumori. 
I risultati che abbiamo ottenuto mostrano l’associazione di TRAP1 alla succinato deidrogenasi 
(SDH), il Complesso II della catena respiratoria. Abbiamo osservato in diversi modelli cellulari 
tumorali che TRAP1 diminuisce la respirazione delle cellule tumorali in vivo inibendo l’attività 
succinato:coenzima Q reduttasi (SQR) del Complesso II. L’inibizione del Complesso II aumenta 
ulteriormente nelle cellule esprimenti TRAP1 durante il saggio di tumorigenesi in vitro, provocando 
l’accumulo di succinato. Questo aumento di succinato induce la stabilizzazione del fattore di 
trascrizione pro-neoplastico HIF1α, favorendo lo switch metabolico necessario per la crescita e la 
progressione tumorale. Infatti, si osserva tumorigenesi in vitro e in vivo solo nelle cellule esprimenti 
TRAP1. 
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1.1 Hallmarks of cancer 
 
Cancer is a highly heterogeneous and complex disease characterized by several alterations in 
basic homeostatic processes. In 2000, Hanahan and Weinberg defined some biological 
processes that lead to the transformation of normal cells into malignant ones. A small number 
of molecular , biochemical, and cellular traits (acquired capabilities) are shared by most or 
probably all types of human cancers. The essential alterations that hallmark cancer and 
regulate malignant growth (Hanahan and Weinberg, 2000) are: 
1. Self-sufficiency in growth signals 
2. Insensitivity to growth inhibitory signals 
3. Evasion of programmed cell death (Apoptosis) 
4. Limitless replicative potential 
5. Sustained angiogenesis 
6. Tissue invasion and metastasis  
 
Genetic mutations leading to neoplastic transformation can occur either in oncogenes 
(dominant gain of function mutations) or in tumor suppressor genes (recessive loss of 
function mutations); products of these genes include protein involved in the regulation of 
diverse biological processes, such as growth, proliferation, apoptosis, metabolism, and DNA 
repair. 
From what we know so far, we can affirm that tumor development proceeds via a process 
formally analogous to Darwinian evolution, in which a succession of genetic changes, each 
conferring a specific advantage to the carrier cell, leads to the progressive process of 
neoplastic transformation, i.e. the conversion of normal cells into cancer cells (Hanahan and 
Weinberg 2000), allowing them to overstep all bounds posed by the surrounding environment 
to tumor formation.  
 
1.1.1  Self sufficiency in growth signals 
Normal cells require growth factors (GF) in order to move from a quiescent state into a 
proliferative one. GF are diffusible protein, which bind cognate receptors on the cell surface 
thus transmitting into the internal space of cells a plethora of signals. Indeed, following 
activation of multiple intracellular signalling cascades, GF control metabolism, entry into the 
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cell cycle and motility, both through regulation of gene expression and through post-
translational modulation of protein function. Conversely, cancer cells acquire autonomy from 
exogenous GFs in several ways: they can (i) become capable to synthesize the GFs they need, 
e.g., sarcomas produce TGFα (Fedi et al., 1994); (ii) overexpress GF-binding receptors, e.g. 
EGF-R /erbB in breast cancer (Slamon et al., 1987); (iii)to structurally change GF receptors 
in order to obtain constitutively active signals, example.g. with truncated versions of EGF 
receptor lacking much of its cytoplasmic domain (Fedi et al., 1994); (iv) switch the isoform 
of the extracellular receptor, in order to express those that are more prone to transmit growth 
signals. Oncogenic mutations can also occur on downstream cytosolic components of GFs 
signaling: a classical example is hyper-activation of the MAP kinase cascade, observed in the 
majority of cancers and caused by mutations in several components of this signaling pathway 
(Dhillon et al., 2007).  
 
1.1.2 Insensitivity to growth inhibitory signals 
Multiple anti-proliferative stimuli operate to counteract growth signals and maintain tissue 
homeostasis. These type of signals include both soluble factors and immobilized inhibitors 
embedded in the extracellular matrix. Antigrowth signals block proliferation, prompting cell 
exit from the cycle, in the G0 quiescent state, which frequently preludes to the acquisition of 
specific differentiation traits. Cancer cells evade these stimuli by modulating components that 
govern the transit of cells through the G1 phase of the cell cycle. A classical pathway altered 
in cancer cells is the one controlled by the protein pRb, encoded by the retinoblastoma tumor 
suppressor gene Rb1. The protein pRB blocks proliferation, because it sequesters the E2F1 
transcription factor, a master switch that controls the transition from G1 into S phase. 
Disruption of this cascade leads to forced proliferation (Goodrich et al., 2006), and 
mutational inactivation of the two Rb1 alleles causes pediatric retinoblastoma and is involved 
in many tumor types.  
Another important player in avoiding post mitotic differentiation is the proto-oncogenic 
transcription factor c-Myc (Dang, Cell, 22, 149, 2012). The resting cell normally expresses 
little c-Myc, whereas cells stimulated by growth factors dramatically increase c-Myc 
expression as an immediate early response gene. c-Myc is constitutively expressed in a wide 
spectrum of cancers and it is associated with aggressive, poor differentiated neoplasias. c-
Myc, in association with the transcription factor Max, activates the expression of genes that 
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directly induce proliferation, such as those encoding Cyclin D2 or CDK4 (Pelengaris et al., 
2002). Cell differentiation is controlled by Mad-Max transcription factor complexes: c-Myc 
over-expression disrupt Mad-Max interaction in several tumors favoring formation of c-Myc-
Max complexes (Pelengaris et al., 2002). Recent works have established a role for c-Myc also 
in cell cycle progression, metabolism, apoptosis and genomic instability (Dang, 2012). 
 
1.1.3  Evasion of programmed cell death (Apoptosis) 
Tumors are characterized by a high proliferation rate that is sustained also by the 
development of a robust anti-apoptotic platform. During apoptosis, lipid asymmetry of 
cellular membranes is disrupted, the cytoplasmic and nuclear skeletons are broken down, the 
cytosol is extruded, the chromosomes are degraded, and the nucleus is fragmented. 
Eventually, the shriveled cell corpses are engulfed by macrophages. 
Signals that elicit apoptosis converge on mitochondria, which respond to stimuli by releasing 
cytochrome c which in turn activates intracellular protease called caspases (this feature will 
be discussed in detail in paragraph 1.4).  
 
1.1.4 Limitless replicative potential 
Mammalian cells carry an intrinsic, cell autonomous program that limits their multiplication, 
independently of cell-to-cell signaling. Once cells have progressed through a certain number 
of doublings, they stop growing and enter a state called senescence. Cellular senescence is 
characterized by a cell cycle arrest that can be triggered by many types of intrinsic and 
extrinsic stress, including telomere malfunction, oncogene activation and tumor suppressor 
gene inactivation (Prieur and Peeper, 2008; Kuilman et al., 2010). Ultimately, most signals 
that induce senescence converge on p53 and pRB, which have been proposed to act as gate-
keeper tumor suppressors (Prieur and Peeper, 2008). From the first description of Oncogene-
Induced cellular Senescence (OIS) over a decade ago (Serrano et al., 1997), many subsequent 
studies have confirmed that OIS prevents cells from undergoing oncogenic transformation in 
vitro. However, it has long been debated whether any in vivo correlate does exist. It is only 
since recent years that evidence has been accumulating indicating that OIS in vivo is a major 
protective mechanism against cancer (Prieur and Peeper, 2008). One strategy used by 
malignancies to replicate in a limitless way is the maintenance of telomeres. The ends of 
chromosomes, called telomeres and characterized by repeats of 6 bp sequence elements, 
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control the number of duplications in a cell life. Each doubling passage leads to a loss of 50-
100 bp of telomeric DNA. When telomeres reach a critical minimal length, their protective 
structure is disrupted. This triggers a DNA damage response (DDR) that can induce a 
transient proliferation arrest, allowing cells to repair their damage. However, if the DNA 
damage exceeds a certain threshold, cells are destined to undergo either apoptosis or 
senescence (Kuilman et al., 2010). Telomeric DNA can be replicated: this process requires 
telomerase, a specialized cellular ribonucleoprotein RNP reverse transcriptase (Blackburn, 
2005). Malignancies, in order to avoid senescence induced by telomeres erosion, upregulate 
telomerases which add hexanucleotide repeats onto the end of telomeric DNA, regenerating 
them continuously (Hanahan and Weinberg, 2000; Blackburn, 2005). 
 
1.1.5 Sustained angiogenesis 
Physiological angiogenesis is the spreading of capillary venules from pre-existing vessels. 
Ischemia and oxygen decrease initiate a cascade of events that stimulates new vessel 
formation in order to increase nutrient and oxygen supply. This complex process requires 
interactions among different cell types, extracellular matrix, growth factors, several 
cytokines. The process of cancer angiogenesis relies on many of the same processes involved 
in the physiological angiogenesis, with the difference that these processes are constitutively 
active in cancer. When the primary tumor mass reaches 1-2 mm of diameter, the tumor 
demand for oxygen and nutrients exceeds the local supply capability and the internal tumor 
regions undergo ischemia. Cancer cells respond to these hypoxic microenvironments with the 
induction of HIF transcription factors, which strongly boost angiogenesis, . In addition to 
hypoxia, other factors can aberrantly upregulate HIF family expression under normoxic 
conditions in tumors, for example inactivating mutations in the tumor suppressor gene von 
Hippel Lindau (VHL), which encodes a protein involved in proteasomal degradation of 
HIF1α  (Denko, 2008). 
The ability of cancer to stimulate new angiogenesis is a pre requisite for the rapid cell 
expansion that preludes to the formation of macroscopic solid tumors (Hanahan and 
Weinberg, 2000; Ellis et al., 2008; Chung et al., 2010). There are many instances in which 
cancer cells upregulate signals that initiate angiogenesis, such as vascular endothelial growth 
factors (VEGF) fibroblast growth factors (FGF 1/2), and down regulate the endogenous 
angiogenesis inhibitors such as β-interferon or thrombospondin-1. New vessels induced by 
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cancer cells are quite different from normal ones because they are tortuous and disorganized. 
Moreover they are leakier than normal: this both contributes to the generation of an 
interstitial hypertension that limits the delivery of anti-neoplastic drugs, and favors the 
spreading of metastases.  
 
1.1.6 Tissue invasion and metastasis  
The capability of neoplastic cells to trespass tissue boundaries, to colonize both adjacent 
districts (invasion) and distant areas, utilizing in this case the blood or the lymph flux 
(metastasis), are characteristic of tumors. The pathological importance of these processes is 
highlighted by the observation that cancer lethality is caused in the vast majority of cases by 
invasive or metastatic tumor masses. Invasion and metastasis are complex events and their 
genetic and biochemical determinants remain not completely understood. 
Epithelial tissues, representing the origins of most solid tumors, are formed by relatively rigid 
sheets of cells. These are separated from the stroma by a basement membrane and are highly 
organized by lateral belts of cell–cell adhesion complexes. During the progression from an in 
situ tumor to an invasive carcinoma, epithelial tumor cells are released from their neighbors 
and breach the basement membrane barrier. This phenomenon requires a complex 
reorganization of tumor cell features, called EMT (Epithelial to Mesenchymal transition; 
Geiger and Peeper, 2009). EMT is an evolutionarily conserved developmental process. 
Indeed during embryonic development, certain differentiated polarized epithelial cells, on 
extracellular cues, undergo profound morphogenetic changes, collectively referred as EMT. 
This is typified by the dissolution of cell–cell junctions and loss of apico–basolateral polarity, 
resulting in the formation of migratory mesenchymal cells with invasive properties (Singh 
and Settleman, 2010) The changes in cell adhesion and migration during tumor invasion are 
reminiscent of EMT developmental process and has an active role in different stages of the 
metastatic cascade such as intravasation. It has been reported that transforming growth factor 
β (TGFβ) acts as a major player in the metastatic process. In non neoplastic cells TGFβ 
mediates growth arrest and apoptosis, but recently Adorno et al. (2009) have identified for 
TGFβ an oncogenic role which would promote mutant p53-mediated suppression of the 
related p63 protein, thus uncovering a new role for p63 in the negative regulation of 
metastasis (Clohessy and Pandolfi, 2009). 
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Several classes of proteins are involved in tethering cells to their surroundings in a tissue, and 
many of these are altered when cells acquire metastatic capacity. Proteins affected include 
cell-cell adhesion molecules (CAMs, for instance E-cadherin) but also integrins that regulate 
interactions between cells and the extracellular matrix and extracellular proteases (Geiger and 
Peeper, 2009). Recently it was proposed that metastasis can evolve following two different 
models and this is crucial under a therapeutic point of view (fig.1).  
 
 
Figure 1. Late and early metastatic cascade model. The late dissemination model postulates that the expansion of 
metastatic clones occurs into the primary tumor, these aggressive cells would have a genetic profile similar to that of primary 
tumor cells. The early dissemination model proposes that mutations accumulate at distant sites, where metastatic cells 
genetically diverge from primary tumor cells (From Klein, 2008). 
 
The first one is the linear progression model, also called the late dissemination model. In this 
model, cancer cells undergo genetic and epigenetic alterations, multiple successive rounds of 
mutations and selections for competitive fitness in the context of primary tumors. After a 
number of such rounds, cells that can proliferate leave the primary accrual site to seed and 
grow in secondary loci. Therefore, this clonal expansion is strictly related to tumor size and, 
more importantly, metastases are genetically similar to primary tumors. 
The second model is the parallel or early dissemination model. This type of progression 
predicts an early dissemination of metastatic founder cells, with no need of accumulating 
mutations in the primary tumor mass. So, a great genetic disparity exists between cells 
derived from the metastatic founder and those grown in the primary tumor, as 
microenvironment becomes the limiting factor in the gathering of site-specific genetic and 
epigenetic mutations (Klein, 2008; Klein, 2009). When tumor cells lose contact with the 
basement membrane they must face another anti-tumor barrier: anoikis. It is a form of 
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programmed cell death which is induced by anchorage-dependent cells detaching from the 
surrounding extracellular matrix. In this way detaching cells are deprived of essential signal 
for growth or survival and die. Tumor cells are capable of evading anoikis. This mechanism 
is achieved through the involvement of constitutive activity of survival pathways that include 
integrin-dependent activation of FAK and subsequent ERK phosphorylation. In addition, 
FAK associates with RIP, thereby inhibiting the association of RIP with Fas and the ensuing 
formation of a death-inducing signalling complex (DISC), thus favoring cell survival. Up-
regulation of CD44 also contributes to survival signals and promotes anoikis resistance 
(Bunek et al., 2011). Moreover amorphosis, or cell death caused by changes in cell shape, 
could hamper metastasis by inducing apoptosis when tumor cells enter “foreign” 
environments. Suppression of this type of cell death is a prerequisite for tumor cells to 
successfully metastasize to distant sites (Geiger and Peeper, 2009). 
 
                          
 
Figure 2. Principal classes of tumor antigens recognized by CTL CD8+ cells. Some proteins expressed or mutated in 
cancer (oncoproteins, mutated self proteins or oncogenic viruses) can be recognized by the immune system if associated to 
MHC I and destroyed by CTL cells (from Kumar et al., 2009) 
After a decade of intensive oncological research and in the light of new observations and 
evidences, Hanahan and Weinberg in 2011 added two new emerging hallmark capabilities 
and two enabling characteristics, crucial to the acquisition of the six hallmark capabilities: 
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1.1.7 Enabling Characteristic: Tumor promoting inflammation 
Links between cancer and inflammation were first made in the 19th century, on the basis of 
the observation that tumors often arise at sites of chronic inflammation and that inflammatory 
cells are present in tumor biopsies. Today the role of inflammation in cancer is established 
but controversial: tumor cells must develop a variety of strategies to escape antineoplastic 
surveillance provided by cells involved in the inflammatory response such as CTL or NK, 
cells that are crucial for the control and elimination of nascent tumors (Mantovani et al., 
2008; Mantovani, 2009; Steer et al., 2010; see Fig. 2). 
Conversely, epidemiological studies have shown that chronic inflammation predisposes 
individual to various types of cancer, and that infections and inflammatory responses are 
connected to cancer in 15-20% of total cases (Balkwill and Mantovani, 2001). There are 
many triggers of chronic inflammation that increase the risk of developing cancer; these 
include microbial infections (for example H. Pylori is associated with gastric cancer and 
gastric mucosal lymphoma; Mantovani et al., 2008) and autoimmune diseases (for example 
the association between inflammatory bowel disease and colon cancer; Mantovani et al., 
2008). Hallmarks of cancer-related inflammation include the presence of inflammatory cells 
and mediators in tumor tissues and tissue remodeling and angiogenesis similar to those 
observed in chronic inflammatory responses. Cancer and inflammation are functionally 
connected in two different ways (fig. 3): 
- inflammatory conditions activate a genetic program in cancer cells that increases the 
rate of neoplastic transformation (extrinsic pathway); 
-  genetic alterations of cancer cells (e.g. oncogene activation) drive the production of 
inflammatory cytokines (intrinsic pathway). Typical examples are activation of the 
receptor tyrosine kinase RET (Borrello et al., 2005), induction of the RAS-RAF 
signaling pathway or of the transcription factor MYC, which drives the development 
of a variety of tumor types. In all these cases, a transcriptional program similar to the 
one occurring during inflammation is induced, with the production of tumor-
promoting inflammatory chemokines and cytokines (Sparmann et al., 2004 ; 
Sumimoto et al., 2006; Shchors et al., 2006). 
13 
 
                        
Figure 3. Pathways that connect inflammation and cancer. Cancer and inflammation are connected by two pathways: the 
intrinsic one activated by genetic events and the extrinsic one due to infectious conditions and inflammation. Both pathways 
converge in the activation of transcription factors (NF-kΒ, STAT3, HIF1α ) that coordinate the production of chemokines 
and cytokines. (from Mantovani et al. 2008) 
 
Tumor suppressor proteins (e.g. VHL, TGFβ and the phosphatase PTEN) can also regulate 
the production of inflammatory mediators.  
Both intrinsic and extrinsic pathways converge on the activation of endogenous transcription 
factors, which elicit cytokine synthesis. Inflammatory pathways are also involved in 
migration, invasiveness and ectopic survival. As an example, the chemokine receptor CXCR4 
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is expressed in tumors, and its expression correlates with the metastasis of colorectal, breast, 
liver and esophageal cancer (Mantovani, 2008). 
 
1.1.8 Enabling Characteristic: Genome instability and mutations 
Cancer cells often increase the rate of mutation in order to obtain mutant genes whose protein 
products contribute to the tumorigenic process. In other words, genome instability is inherent 
to the great majority of human cancer cells because it accelerates the rate of accumulation of 
favorable genotypes (Hanahan and Weinberg, 2011). There are two ways by which tumors 
can do that: through an increase in the sensitivity to mutagenic agents (due to mutations in 
genes whose products are involved in the inactivation of mutagenic molecules before they 
damage DNA), or through a breakdown in one or several components of the genomic 
maintenance machinery (genes codifying for proteins involved in detecting DNA damage and 
activating the repair machinery, or enzymes directly repairing damaged DNA), or both 
(Negrini et al., 2010). The molecular genetic analysis of cancer cell genomes has provided 
compelling evidences of gain and loss of gene copy numbers, finding recurrences of specific 
aberration patterns at particular sites in the genome. 
 
1.1.9 Emerging Hallmark: Evading immune destruction 
Cells and tissues are constantly monitored by the immune system and this surveillance is 
responsible for recognizing and eliminating the vast majority of incipient cancer cells and 
thus nascent tumors. Oncogenic mutations can be recognized also by the immune system. In 
particular cytotoxic T Lymphocytes (CTL) and Natural Killer (NK) cells can efficiently discover and 
destroy cells the express novel or aberrant antigens associated to MHC class I proteins or that do not 
express MHC class I proteins (Kumar et al. 2009, Fig. 2). In order to avoid detection and to limit 
eradication, solid tumors must escape the immune system, both the innate and the adaptative 
arms. This is achieved by the malignant cell through a variety of strategies: for example, 
cancer cells may block the activity of infiltrating CTLs and NK cells by secreting TGF-β or 
other immunosuppressive factors (Yang et al., 2010; Shields et al., 2010). 
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1.1.10 Emerging Hallmark: Reprogramming energy metabolism  
Many observations made during the early period of modern cancer biology identified 
metabolic changes as a common feature of cancerous tissues. One of these features is the 
prevalent use of glycolysis as source of energy, independently of the oxygen availability. 
This phenomenon was discovered by Otto Warburg at the beginning of 20th century (Warburg 
et al., 1927; Warburg, 1956) and cancer glucose avidity is currently used in clinical practice 
to diagnose cancer and dissemination of micro-metastases with the PET (positron electron 
tomography) technique. Today we know that cancer cells are characterized by several 
metabolic alterations, which will be discussed in the next paragraph.  
 
1.2 Metabolic alterations in cancer 
 
Tumor cells have a remarkably different metabolism from that of the tissues which they are 
derived from. Indeed, the metabolism of neoplastic cells mustsustain higher proliferative 
rates and resist oxygen paucity found in the inner tumor mass; at the same time, neoplasms 
are continuously exposed to oxidative insults (Tennant et al., 2010).  
In the third decade of the last century, Warburg measured oxygen consumption and lactate 
production in tumor slices, either in the presence or absence of oxygen. He found that the 
rapidly growing tumor cells consumed glucose at a surprisingly high rate compared to normal 
cells in the presence of oxygen, and most of the glucose-derived carbon was secreted by 
neoplasmsin the form of lactate (Warburg, 1927). Warburg later postulated that this 
phenomenon, termed ‘aerobic glycolysis’, was provoked by mitochondrial impairment and 
was the origin of cancer cell transformation (Warburg, 1956). His observations were almost 
forgotten for almost a century, and metabolic alterations of tumors were simply considered an 
epiphenomenon of changes elicited in the neoplastic cells by mutations in oncogenes and 
tumor suppressor genes. 
In the same period, Crabtree observed that increased glucose availability boosts glycolysis in 
cancer and normal proliferating cells, while inhibiting respiration, an observation now known 
as the ‘Crabtree effect’ (Crabtree, 1928). He further suggested that this observation is 
sufficient to explain the decrease in oxidative phosphorylation-derived ATP in cancer, which 
argues against Warburg’s initial hypothesis that defects in respiration are the cause for 
increased glycolysis. Years later it was suggested that respiration inhibition by glycolysis was 
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caused by glycolysis competing with oxidative phosphorylation for Pi and ADP. However, 
the Crabtree effect does not provide an explanation for the actual cause of the observed 
increased aerobic glycolysis in cancer (Frezza and Gottlieb, 2009). 
Subsequent work showed that mitochondrial function is not impaired in most cancer cells, 
suggesting that the shift towards glycolysis during neoplastic transformation occurs as a 
consequence of regulatory mechanisms. 
We still do not understand exactly what is the advantage obtained by tumor cells in moving 
their metabolic demand towards glucose usage (Fig. 4). The current model postulates that the 
preferential use of aerobic glycolysis offers the following advantages to highly proliferative 
cells. First, it focuses cells on the use of glucose, which is the most abundant extracellular 
nutrient; second, the flux of ATP derived from glycolysis can exceed the one produced 
during OXPHOS, despite the low efficiency of glycolysis, when glucose is provided at a 
sufficiently high concentration; third, glucose utilization provides essential metabolic 
intermediates for the biosynthesis of diverse macromolecules (lipids, proteins and nucleic 
acids) and for anti-oxidative defenses, with the production of NADPH (Vander Heiden et al. 
2009). 
 
                                     
 
 
 
Figure 4. ATP yield of oxidative phosphorylation, anaerobic glycolysis and aerobic glycolysis (Warburg Effect). (from 
Vander Heiden et al., 2009) 
 
Cancer cells need biosynthetic precursors to sustain rapid proliferation, so it is not surprising 
that metabolic activities in cancer cells are very different from those in non-proliferating 
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cells. So, as well as aerobic glycolysis, there are other core fluxes, such as the pentose 
phosphate pathway, the de novo fatty acid synthesis and glutamine-dependent anaplerosis, 
that cancer cells need for their high rate of replication. 
 
1.2.1 The pentose phosphate pathway: 
In order to sustain the rapid proliferation that is a characteristic of tumours, there must be an 
increase in the synthesis of both fatty acids and nucleotide precursors. Cells divert the 
glycolytic intermediates into the Pentose Phosphate Pathway (PPP), either from glucose 6-
phosphate (using the oxidative arm of PPP) or from fructose 6-phosphate (using the non-
oxidative arm of PPP). These intermediates can then be used to reduce nicotinamide adenine 
dinucleotide phosphate (NADP+) to NADPH (from the oxidative arm only) and synthesize 
ribose 5-phosphate, a nucleotide precursor (Tennant et al, 2009). 
 
1.2.2 Fatty acid synthesis: 
Proliferating cells in general and cancer cells in particular require de novo synthesis of lipids 
for membrane assembly. Under conditions where pyruvate dehydrogenase (PDH) is not 
inhibited, pyruvate is converted into acetyl-CoA and enters the trycarboxylic acid (TCA) 
cycle by condensing with oxaloacetate to form citrate (Figure 3A). Citrate is mostly oxidized 
in the TCA cycle to produce reducing potential for the mitochondrial electron transport chain 
(ETC), but it can also be used for fatty acid synthesis in the cytosol. Cytosolic citrate is 
converted back into oxaloacetate and acetyl-CoA by the action of ATP citrate lyase. This 
further supports the anabolic reprogramming observed in tumorigenesis, boosting 
proliferation of tumor cells.  
 
1.2.3 Glutaminolysis: 
There are two major sources of energy and carbon for cancer cells: glucose and glutamine. It 
has been recently proposed that glucose accounts mainly for lipid and nucleotide synthesis, 
whereas glutamine is responsible for anaplerotic re-feeding of the TCA cycle, for amino acid 
synthesis and for nitrogen incorporation into purine and pyrimidine for nucleotide synthesis 
(DeBerardinis et al., 2007). 
Once in the cell, glutamine is initially deaminated to form glutamate, a process catalysed by 
the enzyme glutaminase. Glutamate in turn can be converted into α-ketoglutarate either by a 
second deamination process catalyzed by the enzyme glutamate dehydrogenase or through 
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transamination. On entering the TCA cycle, a-ketoglutarate is metabolized to eventually 
generate oxaloacetate, an important anabolic precursor that will condense with the acetyl-
CoA generated from glycolysis or glutaminolysis to produce citrate (Fig. 5). 
The importance of glutaminolysis in cancer metabolism is evident from the considerable 
release of ammonium in the venous effluent of cancer patients, and by the fact that, with 
time, the majority of patients develop glutamine depletion. In fact, glutaminase has been 
found to be over-expressed in a variety of tumor models and human malignancies, and the 
rate of glutaminase activity correlates with the rate of tumor growth. 
                            
Figure 5. Pathways of glutamine metabolism.The interconnection between glutamine metabolism and glucose metabolism 
is highlighted. Inhibition of glutaminase by compound 968 suppresses oncogenic transformation induced by Rho GTPases. 
GLS, glutaminase; TCA cycle, tricarboxylic acid cycle; MRC, mitochondrial respiratory chain; V, mitochondrial respiratory 
complex V; OAA, oxaloacetate; Asp, aspartate; a-KG, a-ketoglutarate, miR=micro RNA (from Lu et al., 2010). 
 
 
1.3 Mitochondria and tumor 
The molecular mechanisms responsible for the metabolic shift are under intense scrutiny, and 
their unraveling will allow to understand how changes in the metabolic profile can provide 
tumors with a growth advantage (Denko 2008). There are two main mechanisms explored by 
researchers: 
1) Mutations that alter metabolism. Oncogenic mutations, both in oncogenes and in tumor 
suppressor genes can directly influence metabolism. For example, Ras and Akt mutations 
increase glycolytic flux at different levels (Hsu and Sabatini 2008), whereas p53 inhibits 
glycolysis by inducing the expression of TIGAR, which decreases fructose 2-6-biphosphate 
levels (Hsu and Sabatini 2008; Cairns et al. 2011). 
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2) Environmental stresses. A variety of signals reaching the tumor from the surrounding 
environment can modulate the metabolism of the neoplastic cell; these signals include 
hypoxia, acidosis and interstitial pressure. 
 
The first evidences of a direct, causative role of mitochondrial alterations in the tumorigenic 
process were only discovered a decade ago when mutations in succinate dehydrogenase 
(SDH) (Baysal et al., 2000) or fumarate hydratase (FH) (Tomlinson et al., 2002), both 
enzymes of the TCA cycle, were found to be the initiating events of familial paraganglioma 
or leiomyoma and of papillary renal cell cancer, respectively. Soon after the discovery of 
SDH mutations it was proposed that the HIF pathway is activated in the associated tumors 
(Gimenez-Roqueplo et al., 2001) but only four years later it was demonstrated that impaired 
HIFα degradation due to the inhibition of its hydroxylation by PHDs is at the heart of the 
pathology of these tumours.  
HIF stabilization was also found under normoxia (pseudohypoxia), and two models have 
been proposed to explain this observation(Fig. 6). 
                                  
Figure 6.: The physiological roles of SDH in the TCA cycle and the ETC and its potential roles in cancer. During 
succinate oxidation to fumarate by SDHA, the reduction of FAD to FADH2 occurs. Electrons are transferred through the 
iron–sulphur centres on SDHB to ubiquinone (Q) bound to SDHC and SDHD in the inner mitochondrial membrane (IMM), 
reducing it to ubiquinol (QH2). Ubiquinol transfers its electrons through complex III. It was proposed that obstructing 
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electron flow within complex II might support a single electron reduction of oxygen at the FAD site. Superoxide is 
dismutated to hydrogen peroxide which can then leave the mitochondria and inhibit PHD in the cytosol, leading to HIFα 
stabilization. Succinate which accumulate in SDH-deficient tumors, can also leave the mitochondria and inhibit PHD activity 
in the cytosol (From Frezza and Gottlieb, 2009).  
 
The first model proposes that reactive oxygen species (ROS), generated from an impaired 
complex II, inhibit HIFα hydroxylation by PHDs. ROS oxidate iron and ascorbate, that are 
cofactors of PHDs, inactivating them. However, there are controversial data regarding ROS 
production in SDH deficient cells (Ishii et al, 2005; Selak et al., 2006).  
The second model proposes that succinate, whose concentration increases in SDH-deficient 
mitochondria, can serve as a mitochondria-to-cytosol messenger that inhibits PHD activity 
through a feedback mechanism (Selak et al., 2005). Moreover, it was reported  that, similar to 
succinate, the increased fumarate levels observed in FH-deficient HLRCC (Hereditary 
leiomyomatosis and renal cell cancer) tumors also inhibit PHD activity and consequently HIFα 
degradation (Isaacs et al., 2005). 
These two models of pseudo-hypoxic HIF1α stabilization are not necessarily mutually 
exclusive and it is possible that in vivo both ROS and succinate cooperate to inhibit PHD 
activity in SDH-deficient tumors (Frezza and Gottlieb, 2009). 
 
1.4 Hypoxia-inducible factors and cancer 
 
In cancer, the combination of dysregulated cell proliferation and of abnormal blood vessels 
result in severe hypoxia. To adapt to this hostile environment, cancer cells exploit 
physiological responses to hypoxia. Cells respond to hypoxic conditions by activating 
hypoxia-inducible factors (HIFs), which regulate the delivery and consumption of oxygen 
(Semenza, 2012).Cells can increase oxygen consumption in physiological conditions, such as 
in response to proliferation stimuli. The ensuing hypoxic conditions activate HIFs, leading to 
transcription of the VEGF gene, which encodes vascular endothelial growth factor that 
stimulates angiogenesis and increases oxygen delivery. 
HIF is a heterodimeric protein formed by a constitutively expressed subunit (HIFβ, also 
called ARNT) and an oxygen-regulated subunit (HIFα; Boulahbel, 2009). HIF activity is 
regulated by oxygen through proline and asparagine hydroxylation. The hydroxylation of two 
proline residues (Pro 402 and Pro 564) in the ODDD (oxygen-dependent degradation 
domain) in HIF-1α and in HIF-2α is mediated by prolyl hydroxylase domain protein 2 
(PHD2). In humans, the PHD family is composed of three different 2-oxoglutarate (α-
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ketoglutarate) dioxygenases (PHD1, PHD2 and PHD3) that require iron and ascorbate as 
cofactors. This hydroxylation allows the interaction of the ODDD with the pVHL (von 
Hippel–Lindau protein)–ubiquitin E3 ligase, promoting the ubiquitination and subsequent 
proteasomal degradation of HIFα. Under low oxygen, the hydroxylation does not occur, as 
the required oxygen atoms are obtained from molecular oxygen, whereas 2-oxoglutarate 
provides electrons and is then decarboxylated to succinate. Thus, the interaction between 
HIF1α and pVHL is prevented. As a result, HIFα is stabilized, forms a heterodimer with 
HIFβ and promotes the expression of target genes. The number of direct HIF target genes is 
currently greater than 800 (Semenza, 2012). 
 
 
HIFs play key roles in many crucial aspects of cancer biology including angiogenesis, stem 
cell maintenance, metabolic reprogramming, autocrine growth factor signaling, epithelial-
mesenchymal transition, invasion, metastasis, and resistance to radiation therapy and 
chemotherapy. This is achieved through modulation of several specific HIF-regulated genes 
(Fig 7): 
- Metabolic reprogramming: HIF-1 mediates the expression of genes encoding glucose 
transporters (GLUT1 and GLUT3), glycolytic enzymes (Hexokinase 1 and 2, lactate 
dehydrogenase, pyruvate kinase M2). 
- Angiogenesis: HIF-1 controls the expression of several genes encoding angiogenic 
growth factor, as VEGF, stromal-derived factor 1 (SDF1) or placental growth factor 
(PGF). 
- Epithelial–mesenchymal transition: HIF-1 induces the transcription of genes that 
block the expression of E-cadherin and other proteins that are responsible for the 
architecture of the cytoskeleton, for cell-cell adhesion or other features of epithelial 
cells. 
- Invasion and metastasis: HIF activates also the transcription of genes which encode 
for proteases that degrade or remodel the extracellular matrix and that favor 
extravasation of cancer cells at metastatic sites. 
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Figure 7 HIF target genes encode proteins involved in crucial aspects of cancer progression. (a) HIF target genes that 
promote cell immortalization, stem cell self-renewal, and autocrine growth and survival include those encoding 
adrenomedullin (ADM), endothelin 1 (EDN1). (b) HIF-1 target genes involved in metabolic reprogramming include glucose 
transporter 1 and 3 (GLUT1, GLUT3), hexokinase 1 and 2 (HK1, HK2), glycolytic enzymes aldolase A (ALDOA), enolase 
1 (ENO1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), phosphofructokinase L (PFKL), phosphoglycerate kinase 
1 (PGK1), pyruvate kinase M2 (PKM2), and lactate dehydrogenase A (LDHA). (c) HIFs stimulate tumor vascularization by 
activating transcription of the genes encoding VEGF, stromal-derived factor 1 (SDF1), placental growth factor (PGF), 
platelet-derived growth factor B (PDGFB), and angiopoietin 1 and 2 (ANGPT1, ANGPT2). (d) HIF target genes that 
promote epithelial–mesenchymal transition include those encoding inhibitor of differentiation 2 (ID2), snail 1 and 2 (SNAI1, 
SNAI2), transcription factor 3 (TCF3), TGFA, vimentin (VIM), and zinc finger E-box-binding homeobox 1 and 2 (ZEB1, 
ZEB2). (e) HIF target genes promoting invasion and metastasis include those encoding autocrine motility factor (AMF; also 
known as GPI), angiopoietin-like 4 (ANGPTL4), cathepsin C (CTSC), lysyl oxidase (LOX), LOX-like 2 and 4 (LOXL2, 
LOXL4), L1 cell adhesion molecule (L1CAM), Met proto-oncogene/hepatocyte growth factor receptor (MET), matrix 
metalloproteinase 2, 9, and 14 (MMP2, MMP9, MMP14), and the urokinase plasminogen activator receptor (PLAUR) (From 
Semenza, 2012). 
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1.5 Chaperones in cancer 
 
In cancer cells, the aberrant stimulation of a variety of biological routines, which encompass 
proliferation, growth, motility and survival, in the presence of several mutant proteins and 
under the constitutive pressure of hyperactivated kinase signalling, requires a highly efficient 
process of protein quality control. This is carried out by molecular chaperones, which are 
involved in the correct folding of nascent polypeptides and in the productive assembly of 
multimeric protein complexes, while minimizing the danger of aggregation in the protein-rich 
intracellular environment. These proteins also control the conformational changes associated 
to molecular dynamics, as in the case of propagation of signals through reversible 
phosphorylations, and in the regulation of protein degradation and turn-over (Akerfelt et al., 
2010; Liberek et al., 2008). The mechanism that cells use to ensure the quality of intracellular 
proteins is the selective destruction of misfolded or damaged polypeptides. In eukaryotic 
cells, a large ATP-dependent proteolytic machine, the 26S proteasome (Ravid and 
Hochstrasser, 2008) prevents the accumulation of non-functional, potentially toxic proteins. 
This process is of particular importance in protecting cells against harsh conditions (for 
example, heat shock or oxidative stress) and in a variety of diseases (for example, cystic 
fibrosis and the major neurodegenerative diseases).  
Heat shock proteins (HSP) are an important protein family of intracellular chaperones. The 
heat shock response is a highly conserved mechanism in all organisms from yeast to humans 
that is induced by extreme proteotoxic insults such as heat, oxidative stress, heavy metals, 
toxins and bacterial infections. To face these and many other stress conditions, HSPs regulate 
protein-protein interactions in several conditions, maintaining the correct polypeptide folding 
in a plethora of dynamic situations, assisting in the establishment of proper protein 
conformational changes, also preventing unwanted protein aggregations. HSPs also 
contribute to the stabilization of partially unfolded proteins, and to the transport of proteins 
across cell membranes, and are also involved in protein degradation and in the control of 
signaling activation. Their conservation among different eukaryotes suggests that heat shock 
proteins are essential for cell survival (Richter et al., 2010; Hishiya and Takayama, 2008). 
The 90-kDa heat shock proteins (HSP90)  are crucially involved in cell signaling, 
proliferation, and survival, and are ubiquitously expressed in cells. Many proteins in tumor 
cells are dependent upon the HSP90 protein folding machinery for their stability, refolding, 
and maturation (Landriscina et al., 2009). 
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HSP90 is an evolutionarily conserved molecular chaperone that participates in stabilizing and 
activating more than 200 proteins —referred to as HSP90 ‘clients’- many of which are 
essential for constitutive cell signaling and adaptive responses to stress. To accomplish this 
task, HSP90, the chaperone HSP70, and additional proteins termed co-chaperones form a 
dynamic complex known as the HSP90 chaperone machine (Taipale et al., 2010; Neckers et 
al., 2009). Cancer cells use the HSP90 chaperone machinery to protect an array of mutated 
and over-expressed oncoproteins from misfolding and degradation. Therefore, HSP90 is 
recognized as a crucial facilitator of oncogene addiction and cancer cell survival. For all these 
features HSP-90 is an important therapeutic target in cancer (Whitesell and Lindquist, 2005). 
The first HSP90 inhibitor, 17-AAG (tanespimycin), entered clinical trials in 1999. In 2004, a 
second HSP90 inhibitor, 17-DMAG (alvespimycin), entered in clinical experimentation. 
Owing to extensive efforts in rational drug design and discovery, HSP90 inhibitors are 
currently undergoing clinical evaluation in cancer patients (Trepel et al., 2010; see Table 1). 
 
                                     
Table 1. TRAP1 antagonists under preclinical/clinical evaluation (Landriscina et al, 2009) 
 
HSP90 is characterized by a unique ATP-binding pocket. The conserved chaperone structure 
consists of three domains: an amino terminal region (N domain) that contains an ATP and 
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drug-binding site and co-chaperone-interacting motifs; a middle (M) domain that provides 
docking sites for client proteins and co-chaperones, and that participates in forming the active 
ATPase; and a carboxy-terminal (C) domain that contains a dimerization motif, a second 
drug-binding region and interaction sites for other co-chaperones. Dimerization of two 
HSP90 protomers through their C domains is necessary for chaperone function. Although 
HSP90 is primarily a cytoplasmic protein, it was also found in organelles such as 
mitochondria (Trepel et al. 2010). 
Mammalian cells also express two compartmentally restricted HSP90 homologues: 
- Glucose-regulated protein 94 (GRP94) found in the endoplasmic reticulum (ER); 
- Tumour necrosis factor receptor-associated protein 1 (TRAP1) localized into mitochondria.  
Like other HSP90 proteins, both GRP94 and TRAP1 possess ATPase activity but both lack 
known co-chaperones. Recent studies suggest that GRP94 is essential for the maturation and 
secretion of insulin-like growth factors, which are autocrine mitogens that have a key role in 
transformation. ATP binding and hydrolysis are essential for the chaperone activity of 
GRP94, and a comparison of the nucleotide-binding pocket of GRP94 with that of HSP90 
suggests that GRP94-specific inhibitors can be designed. In light of these recent findings, 
GRP94 should be evaluated as a bona fide anticancer target. (Trepel et al. 2010). 
 
The mitochondrial chaperone TRAP1 
 
TRAP1 (also known as HSP75) is a molecular chaperone of 75 kDa, homologous to HSP90 
(Chen et al., 2005). TRAP1 was first identified as a HSP90-like chaperone while screening 
for proteins associated with the cytoplasmic domain of the type 1 Tumor Necrosis Factor 
Receptor-1 (TNFR-1), using the yeast two-hybrid system. A positive clone bound to the 
NH2-terminal domain of TNFR-1 in vitro was designated as TNFR1-Associated Protein-1 
(TRAP1; Song et al., 1995). The interaction between TNFR-1 and TRAP1 turned out to be an 
artifact. Indeed, translation of the TRAP-1 mRNA generates a precursor protein of 704 amino 
acids, containing a mitochondrial import sequence of 59 amino acids, which is removed upon 
organelle import (see Fig. 8), and TRAP1 expression is restricted to mitochondria. 
26 
 
                                             
Figure 8. TRAP1 structure (Sturlese and Mammi, unpublished structure) 
 
TRAP1 displays a higher ATP binding affinity than HSP90, with a typical ATPase cycle 
(Felts et al., 2000), but it does not bind the classical HSP90 co-chaperones (p23 and Hop), 
even if this does not exclude the possibility that TRAP1 binds other co-chaperones, not yet 
identified. . See Table 2 for a comparison between TRAP1 and HSP90. 
 
                         
Table 2. Comparison between TRAP1 and HSP90 (Altieri et al., 2011). 
 
The expression of TRAP1 is low or absent in the mitochondria of normal tissues (with the 
exception of the brain and testis) but is markedly increased in tumor mitochondria (Kang et 
al., 2007). Accordingly, microarray analyses identified TRAP1 as one of the target genes 
27 
 
upregulated by the Myc oncogene (Coller et al., 2000). Many chaperones are endowed with a 
protective role against acute and chronic stress, and an anti-apoptotic function is emerging for 
TRAP1 as well. Indeed, in natural killer cells TRAP1 protects from Granzyme M-mediated 
generation of ROS and by the ensuing apoptosis (Hua et al., 2007) It was proposed a general 
function of TRAP1 in the protection of mitochondria from oxidative stress. Accordingly, 
TRAP1 was also found to be a substrate of the serine/threonine kinase PINK-1, whose 
mutations cause an autosomal recessive form of Parkinson’s disease, whose pathogenesis 
largely involve oxidative stress of dopaminergic neurons. TRAP1 phosphorylation by PINK1 
protects cells from apoptosis (Pridgeon et al., 2007). This finding supports the notion that 
TRAP1 plays a role in Parkinson’s disease, but also suggests that Ser phosphorylation may be 
an important regulatory mechanism in TRAP1 function. An anti-oxidant role of TRAP1 
could also be important in tumorigenesis. In human osteosarcoma SAOS-2 cells and colon 
carcinoma cells high TRAP1 levels elicit resistance to oxidants and chemotherapeutics 
(Costantino et al., 2009). TRAP1 overexpressing cells become more resistant to 
chemotherapeutics, suggesting a role for the anti-apoptotic effect of TRAP1 in tumorigenesis. 
Consistently, Fluorouracil (FU) resistant colon carcinoma cells and other tumor cells 
upregulate TRAP1 protein levels (Montesano Gesualdi et al., 2007). The importance of 
TRAP1 in neoplastic transformation is further supported by the finding that mitochondria 
from tumor cells contain TRAP1 in a complex with HSP90, and that disabling the ATPase 
activity of these chaperones leads to the selective death of neoplastic cells (Kang et al., 2007). 
Moreover TRAP1 silencing in prostate cancer cell lines caused apoptosis, as did its targeting 
with mitochondria-specific HSP90 inhibitors (Leav et al., 2009), and TRAP1 inhibition leads 
to the collapse of mitochondrial integrity, cytochrome c release, and caspase activation in 
several tumor cell lines and in several murine tumor models with little effect on non-
transformed cells and minimal in vivo toxicity (Kang et al., 2009; Kang et al., 2007). Notably, 
TRAP1 could also have a role as a cancer biomarker, as its expression is increased in 62% of 
all colorectal carcinomas, and in 100% of metastatic colorectal carcinomas (Landriscina et 
al., 2009). 
Taken together, these observations indicate that TRAP1 displays a relevant role in 
tumorigenesis, and that it may inhibit some key apoptogenic events in mitochondria, whose 
loss of regulation could contribute to the process of neoplastic transformation. 
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2. Materials and Methods 
 
Cell cultures and transfections 
Human SAOS-2 osteosarcoma cells, human cervical cancer HeLa cells and human HCT-116 
colorectal carcinoma cells were purchased from ATCC. MEF cells, obtained from C57BL/6J 
mice through SV40-immortalization, were a generous gift of Dr R. Stein, Tel Aviv 
University. All these cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (Invitrogen). RWPE-1 normal prostate epithelial 
cells (transfected with a single copy of the human papilloma virus 18) and RWPE-2 cell line, 
which was obtained by ( transformation of RWPE-1 cells with Ki-Ras , were grown in 
keratinocyte medium (Gibco) supplemented with EGF and bovine pituitary extract; 100 
units/ml penicillin and 100 μg/ml streptomycin were added to all media, and cells were kept 
in a humidified atmosphere of 5% CO2/95% air at 37°C. 
TRAP1 stable interference was achieved by transfecting cells with a panel of TRAP1 
shRNAs from Sigma: CCGGTCCCTGTACTCAGAA; 
CCGGCAGAGCACTCACCCTACTATGCTCGAGCATAGTAGGGTGAGTGCTCTGTTT
TTG; 
CCGGTGGTTCTGGAGTGTTTGAAATCTCGAGATTTCAAACACTCCAGAACCATTT
TTG. 
HIF1α stable interference was achieved with the following HIF1α shRNAs from Sigma: 
CCGGCCAGTTATGATTGTGAAGTTACTCGAGTAACTTCACAATCATAACTGGTTT
TT; 
CCGGTGCTCTTTGTGGTTGGATCTACTCGAGTAGATCCAACCACAAAGAGCATTT
TT). Scrambled shRNAs were used as negative controls. Stable interfered cells were selected 
in 0.8 μg/ml puromycin (Sigma). TRAP1 mutant lacking the mitochondrial import sequence 
(ΔN TRAP1) was a Δ1–59-Myc construct (generated as in Amoroso et al., 2012). For the 
expression of TRAP1 cDNA (cloned in a pCMV6 vector, Origene), MEF cells were 
transfected with Lipofectamine 2000 (Invitrogen) and selected in G418 (0.5 mg/ml; Sigma). 
The rate of cell growth was measured with a ScepterTM cell counter (Millipore). 
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Tissue samples 
Specimens from both tumor and normal, non-infiltrated peritumoral mucosa were obtained 
from patients with colorectal carcinoma during surgical cancer removal, after an expressed 
written informed consent to use biological specimens for investigational procedures was 
obtained from all patients. Samples were cut into 125 mm3 pieces and one specimen was 
fixed in formalin to confirm the histopathological diagnosis, while the others were frozen in 
liquid nitrogen for further analyses. TRAP1 expression was increased in all samples from 
metastatic neoplasias and in the majority of initial, non-metastatic tumors with respect to the 
non-infiltrated surrounding mucosa. For ETC complex II evaluations, at least three samples 
with increased TRAP1 expression and three samples without any TRAP1 expression changes 
were analyzed. 
 
 
In vitro tumorigenesis assays 
For the focus forming assay, 106 cells were plated in 10 cm Petri dishes (BD Falcon) in 
Dulbecco’s modified Eagle’s (DMEM) medium supplemented with 10% fetal bovine serum 
(Gibco). When cells reached sub-confluence, serum concentration was decreased to the 
reported values, which did not induce cell death per se, and changed every 4th day. 
Mitochondria utilized for the determination of ETC complex enzymatic activities or cell 
lysates used for Western immunoblot assays were obtained at the 15th day after serum 
decrease, i.e. 1-2 days before cells that did not form foci started a massive death process (see 
below for sample preparation). 25 days after serum decrease foci appeared as thick masses 
and cords of cells. Plates were washed in PBS, fixed in methanol for 30 min and foci colored 
with GIEMSA solution for 1 h. After washing in deionized water, size and number of foci 
was analyzed with an Image Analyzer custom software (Rasola et al., 2007). For the soft agar 
assay, cells were grown in 6 cm Petri dishes covered by a bottom layer composed by DMEM 
medium mixed with low melting point agarose (Promega) at a final concentration of 1.0%, 
and by a top layer of DMEM medium supplemented with 0.5% serum and mixed with low 
melting point agarose at a final concentration of 0.6%. Cells (3x105) were added during the 
preparation of the upper layer, where they remained embedded. Dishes were then maintained 
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in a humidified atmosphere of 5% CO2-95% air at 37°C for three weeks, adding medium 
(DMEM 0.5% serum) on the top of the two layers every 7th day. At the 25th day, dishes were 
washed in PBS and colonies were stained with Crystal Violet 0.05% and analyzed with 
Image Analyzer software. 
 
 
In vivo tumorigenesis assays 
Experiments were performed in 5-week-old female CD1 nude mice (Charles River 
Laboratories) treated in accordance with the European Community guidelines. Twelve mice 
were injected subcutaneously bilaterally in the flanks with 1.5x107 SAOS-2 mock or 
shTRAP1 cells in 200 μl of serum-free sterile PBS. In a subset of animals, tumor growth was 
favored by injecting cells in PBS mixed with Matrigel in a 1:1 ratio. Tumor growth was 
evaluated on alternate days by calliper measuring. After three weeks, mice were sacrificed 
and tumors stored at -80°C or fixed in formaldehyde and maintained in 70% ethanol for 
immunohistochemical analyses. 
 
 
Cytofluorimetric analyses 
Flow cytometry recordings were performed to determine cell death, as described (Fassetta et 
al., 2006; Gramaglia et al., 2004), and mitochondrial mass. Briefly, cells were incubated at 
37°C in 135 mM NaCl, 10 mM HEPES, 5 mM CaCl2 with FITC-conjugated Annexin-V 
(Boehringer Mannheim) and propidium iodide (PI, 1 μg/ml; Sigma), to detect phosphatidyl-
serine exposure on the cell surface (increased FITC-conjugated Annexin-V staining) and loss 
of plasma membrane integrity (PI permeability and staining). N-acrydine orange (NAO 20 
μM, Invitrogen), which binds to cardiolipin in mitochondrial membranes, was utilized to 
evaluate mitochondrial mass. Samples were analyzed on a FACS Canto II flow cytometer 
(Becton Dickinson). Data acquisition and analysis were performed using FACSDiva 
software. 
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Mitochondria purification and quantification 
Mitochondria were isolated after cell disruption with a glass-Teflon or electrical potter 
(Sigma) in a buffer composed by 250 mM sucrose, 10 mM Tris-HCl, 0.1 mM EGTA-Tris, 
pH 7.4. Nuclei and plasma membrane fractions were separated by a first mild centrifugation 
(700g, 10 min); mitochondria were then spinned down at 7000g, 10 min, and washed twice 
(7000g, 10 min each). All procedures were carried out at 4°C. In order to define 
submitochondrial protein localization, isolated mitochondria were digested with trypsin at 
different concentrations at 4°C for 1h. Where indicated, 0.1% SDS was added before trypsin. 
Trypsin was then inactivated with a protease inhibitor cocktail (Sigma). Mitochondria were 
quantified using a BCA Protein Assay Kit (Thermo Scientific-Pierce). 
 
 
Western immunoblots, immunoprecipitations and crosslinkings 
For Western immunoblots analyses, cells were lysed at 4°C in a buffer composed by 140 mM 
NaCl, 20 mM Tris-HCl pH 7.4, 5 mM EDTA, 10% glycerol, 1% Triton X-100, in the 
presence of phosphatase and protease inhibitors (Sigma). Lysates were then cleared with a 
centrifugation at 13000g for 30 min at 4°C, and proteins were quantified using a BCA Protein 
Assay Kit (Thermo Scientific-Pierce).  
Protein immunoprecipitations were carried out on 3 mg of total cellular extracts. Lysates 
were pre-cleared with an incubation with protein A-Sepharose (Sigma) for 1 h at 4°C and 
then incubated in agitation for 18 h at 4°C with the antibody conjugated to fresh protein A-
Sepharose beads. Where indicated, an anti mouse IgG was added as a negative isotype 
control. Beads were then washed several times in lysis buffer. 
For the crosslinking assays, isolated mitochondria were suspended in PBS buffer and 
incubated with dimethyl 3,3-dithiobis-propionimidate (DTBP, Sigma, 1 mM), a membrane-
permeable, homo-bifunctional reagent that reacts with the primary amines of two interacting 
proteins at an average distance of about 8 Å (Giorgio et al., 2009), for 15 minutes at room 
temperature and then spinned at 7000 rcf for 5 minutes. Pellet was then lysed as above, and 
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lysates were ultracentrifuged at 100000 rcf for 25 minutes at 4°C prior to TRAP1 
immunoprecipitation.  
Proteins extracted from total cell lysates or from immunoprecipitations were then boiled for 5 
min in Laemmli sample buffer, separated in reducing conditions on SDS-polyacrylamide gels 
and transferred onto Hybond-C Extra membranes (Amersham) following standard methods. 
Primary antibodies were incubated 16 h at 4°C, and horseradish peroxidase-conjugated 
secondary antibodies were added for 1 h. Proteins were visualized by enhanced 
chemiluminescence (Millipore). Anti TRAP1 (sc-13557), anti SDHA (sc-166947), anti 
SDHB (sc-59688) mouse monoclonal antibodies and anti actin (sc-1615) goat polyclonal 
antibody were all from Santa Cruz; anti HIF1α (610959) mouse monoclonal antibody was 
from Becton Dickinson; anti GAPDH (MAB374) mouse monoclonal antibody was from 
Chemicon; anti Bcl-X (54H6) rabbit polyclonal antibody was from Cell Signaling; anti Cyp-
D (AP1035) mouse monoclonal antibody was from Calbiochem; the anti mouse IgG was 
from Thermofisher; anti COXII (12C4F12) mouse monoclonal antibody was from 
MitoSciences (Total OXPHOS Human Antibody Cocktail, MS601); anti Hsp90 (610418) 
mouse monoclonal antibody was from BD Transduction Laboratories; mouse monoclonal 
anti Complex II imunocapture antibody was from MitoSciences. 
 
 
Blue native polyacrylamide gel electrophoresis (BN-PAGE) 
BN-PAGE experiments were performed on mitochondria isolated as described. ETC 
complexes and super-complexes were extracted from 200 μg of mitochondria in a buffer 
composed by 1M aminocaproic acid, 50 mM Bis Tris pH 7, in the presence of 1% digitonin 
at 4°C for 2 min. After extraction mitochondria were spinned at 100000 rcf for 30 min and 
supernatants were collected and loaded on polyacrylamide 3-12% Bis Tris pre-cast gradient 
gels (Invitrogen) after addition of sample buffer added of G250 (Invitrogen). Bands were then 
visualized with a 18 h Coomassie Blue staining. Bands corresponding to ETC complex II and 
IV were cut and run on a normal SDS PAGE, in order to separate single protein components 
and to identify them by Western immunoblotting. 
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ETC complex II and IV activity assays 
To measure the enzymatic activity of respiratory chain complex II, cells or biopsies were 
homogenized with an electric potter (Sigma) in a buffer composed by 250 mM sucrose, 10 
mM Tris-HCl, 0.1 mM EGTA-Tris, pH 7.4, Percoll 10%, protease and phosphatase inhibitors 
and mitochondria isolated as described above. Mitochondrial enriched fractions (40 μg per 
trace) were used for spectrophotometric recordings (600 nm, 30°C) of the reduction of 2-6 
dichlorophenolindophenol (DCPIP). Mitochondria are preincubated for 10 min at 30°C in a 
buffer composed by potassium phosphate 25 mM pH 7.2, sodium succinate 20 mM, 
alamethicin 5 μM. After the pre-incubation time, sodium azide (500 μM), antimycin A (1 
μM), rotenone (1 μM) and DCPIP (50 μM) were added for 1 min to the medium. Reaction 
started after the addition of an intermediate electron acceptor (Coenzyme Q1, 6.5 μM; 25). 
Each measurement of ETC complex II activity was normalized for citrate synthase (CS) 
activity.  
To measure CS activity, citrate formation is determined with a spectrophotometer as an 
increase in absorbance at 420 nm, 37°C. Reaction buffer was composed by 100 mM Tris-HCl 
pH 8, 100 μM DTNB, 300 μM Acetyl -CoA, 500 μM Oxaloacetate.  
To measure the enzymatic activity of respiratory chain Complex IV, cells were subjected to 
three cycles of freezing and thawing in liquid nitrogen. These cellular homogenates were 
used for spectrophotometric recordings (550 nm, 37°C) of the oxidation of reduced 
cytochrome c, nm (ε=18.5 mM−1 cm−1) in a buffer composed by potassium phosphate 100 
mM pH 7, water and laurel-maltoside 10% p/v. The reaction started by the addition of 
cellular homogenates and the decrease in absorbance was followed for 3 min. Reduced 
cytochrome c was prepared immediately before use by adding a few grains of sodium 
dithionite. Each measurement of ETC complex IV activity was normalized for protein 
amount and for CS activity, as above. 
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Oxygen consumption rate (OCR) experiments 
The rate of oxygen consumption was assessed in real-time with the XF24 Extracellular Flux 
Analyzer (Seahorse Biosciences), which allows to measure OCR changes on adherent cells, 
after up to four sequential additions of compounds. Cells (5x104/well) were plated the day 
before the experiment in a DMEM/10% serum medium; experiments were carried out on 
confluent monolayers. Before starting measurements, cells were placed in a running DMEM 
medium (supplemented with 25 mM glucose, 2mM glutamine, 1mM sodium pyruvate, 
without serum and sodium bicarbonate) and pre-incubated for 30 min at 37°C in atmospheric 
CO2. OCR values were then normalized for the protein content of each sample. An accurate 
titration with the uncoupler FCCP was performed for each cell type, in order to utilize the 
FCCP concentration (20-300 nM, depending on the cell type) that maximally increases OCR. 
To exclude that OCR differences between mock and shTRAP1 cells were caused by changes 
in succinate availability inside mitochondria, the cell-permeable analogue methyl-succinate 
was used, and no appreciable difference was recorded. 
 
 
Immunohistochemical analyses 
Four thick serial sections of paraffin-embedded tumor samples were stained with 
haematoxylin-eosin (H&E) and Azan-Mallory. For immunohistochemistry analysis with 
TRAP1, HIF1α and MIB1/Ki67, briefly after dewaxing and hydration, sections were 
incubated in EDTA buffer at pH 8.0 or in citrate buffer 5 mM at pH 6.0, respectively, in a 
microwave oven for antigen retrieval. Afterward, sections were treated with ULTRA V Block 
for 5 min (Thermo Scientific) and incubated for 60 min with the primary antibody (anti-
HIF1α monoclonal antibody, 1:50, was from BD Biosciences and anti- MIB-1/Ki67 
GTX73546 monoclonal antibody, 1:100, was from GeneTex). Sections were subsequently 
incubated with rabbit Primary Antibody Amplifier Quanto for 10 min (Thermo Scientific). 
Then, after the buffer wash step, sections were treated with HRP Polymer Quanto for 10 min. 
Immunoreactivity was visualized with 3-30-diaminobenzidine (DAKO).  
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Immuno-electron microscopy analyses 
To perform immuno-electron microscopy experiments, cells were fixed with a mixture of 4% 
paraformaldehyde and 0.05% glutaraldehyde, antibody-labeled using the gold-enhanced 
protocol, embedded in Epon-812, and cut. EM images were acquired from thin sections using 
a FEI Tecnai-12 electron microscope equipped with an ULTRA VIEW CCD digital camera 
(FEI). 
 
Determination of intracellular succinate level 
To determine the intracellular succinate level, cells were first washed three times in PBS at 
room temperature and then quickly scraped in a buffer composed by 30% acetonitrile, 50% 
methanol and 20% water on ice. Lysates were collected and frozen in a cold solution with 
methanol and dry ice for 5 min in order to favor the metabolic quenching needed for 
metabolites extraction. The insoluble material was immediately spun down in a cooled 
centrifuge at 16000 g for 15 min at 0°C and the supernatant was collected for subsequent 
analysis. Metabolites were separated using a liquid chromatography (LC) system and 
analyzed by mass spectrometry (MS). A ZIC-HILIC column (4.6 mm×150 mm, guard 
column 4.6 mm×10 mm, Merck, Germany) was used for LC separation using formic acid, 
water acetonitrile as component of the mobile phase. Results were normalized to protein 
concentration, measured from parallel cell culture using BCA kit as described above. 
 
Intracellular ATP determination 
Intracellular ATP was quantified by the luciferin/luciferase method using the ATP 
determination kit by Invitrogen/Molecular Probes following manufacturer’s instructions. 
Cells were kept for two hours in the different experimental conditions, washed in PBS, lysed 
in boiling water to avoid ATPase activity. 2.5 μg of proteins were analyzed in a 100 μl final 
volume. Each experiment was performed in triplicate. 
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3. Results 
3.1 Mitochondrial TRAP1 promotes neoplastic transformation 
We found that TRAP1 is localized in mitochondria of cancer cell models, as expected (Altieri et al., 
2011). In fact, when we analyzed the subcellular distribution of the chaperone TRAP1 in tumor cell 
models, we found it into mitochondria, both with immuno-electron microscopy inspection (Fig. 9A) or 
with mitochondrial fractionation (Fig. 9B). 
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Figure 9. TRAP1 localization. (A) Immuno-electron microscopy inspection shows most of TRAP1 along the inner mitochondrial 
membranes (arrows). (B) Trypsin treatment of isolated mitochondria shows that TRAP1 is partially cleaved at the highest trypsin 
concentration, but it displays a pattern similar to that of the matrix protein cyclophilin D (CyP-D), thus indicating that most of TRAP1 is 
found in the internal mitochondrial compartments Blots were probed for Bcl-X as a marker of the outer mitochondrial membrane and for 
CyP-D as a matrix marker. 
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In order to study TRAP1 functions, we decided to modulate TRAP1 expression levels in different 
tumor cell models, using different short hairpin RNAs (shRNA), in order to be sure that there are not 
off-target effects, due to the use of shRNA. In Fig. 10, there are the tumor cell models we used: SAOS-
2 osteosarcoma cells, HCT116 colon carcinoma cells and HeLa cervix carcinoma cells and in which 
TRAP1 expression had been interfered (dubbed shTRAP1 cells). 
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Figure 10. Different tumor cell models in which TRAP1 expression has been downregulated. In SAOS-2 cells, HCT116 cells and 
HeLa cells, TRAP1 expression has been modulated using different short hairpin RNA. 
 
 
We wanted to understand if TRAP1 could have a role in the tumorigenic process, so we performed in 
vitro tumorigenesis assays: focus forming and soft agar. In the focus forming assay, only cancer cells, 
that have lost contact inhibition, can overgrow and form foci. There is foci formation only in mock 
cells, but not in tumor cells in which TRAP1 expression has been downregulated (Fig. 11).  
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Figure 11. SAOS-2 cells and HCT116 cells lose the capability to form foci after knocking-down TRAP1 expression. Data indicate 
the total focus area at the 25th experimental day with low serum. Representative areas showing focus growth are reported. 
 
 
We performed also a second in vitro tumorigenic assay, the soft agar assay. In this assay, cells are 
embedded in an agar matrix and only cancer cells that escape anoikis cell death signal, can grow and 
form colonies. Again we observed colonies formation only in mock cells, but not in shTRAP1 cells 
(Fig. 12), both in SAOS-2 cells and HeLa cells. 
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Figure 12. SAOS-2 cells lose the capability to form colonies in soft agar after knocking-down TRAP1 expression. Data indicate the 
total colony area at the 20th experimental day with low serum. Representative areas showing colony growth are reported. 
 
 
From these in vitro tumorigenesis assays, we can conclude that the down-regulation of TRAP1 
expression by RNA interference abrogate any transforming potential. In fact, shTRAP cells became 
unable both to form foci and to grow in soft agar (Fig. 11 and 12). 
The absence of growth of foci or colonies in shTRAP cells is not due to differences in the growth rate 
between mock cells and shTRAP cells, as it is possible to see in Fig. 13. TRAP1 modulation has no 
effect on cell growth rate. 
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Figure 13. Rate of cell growth in different tumor cell modes, with or without TRAP1 downregulation. There is no difference in the 
rate of cell growth in different tumor cell models (SAOS-2 cells, HCT116 cells and HeLa cells) in which TRAP1 expression has been 
downregulated. 
From the experiments performed so far, we can conclude that TRAP1 is necessary for in vitro 
tumorigenesis. We decided to understand which is the role of TRAP1 in vivo. So we decided to 
perform in vivo tumorigenesis. We injected mock and shTRAP SAOS cells in nude mice (Fig. 14) and 
notably, shTRAP1 tumor cells lost the ability to develop tumor masses when injected, both with or 
without matrigel, that is used to mimics the extracellular matrix.  
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Figure 14. Kinetics of tumor growth in nude mice after injection of SAOS-2 cells without or with a Matrigel bolus (left and right, 
respectively); representative tumors grown with Matrigel are shown on the right. All along the Figure, data are reported as mean±SD 
values (n≥3). 
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Conversely, when the TRAP1 cDNA was expressed in non-transformed cells, either RWPE-1 
prostate epithelial cells or fibroblasts (Mouse Embryonic Fibroblasts), these acquired the capacity to 
form colonies in soft agar (Fig.15). 
      TRAP1
co
lo
ny
 a
re
a 
(a
.u
.)
0.4
0.8
1.2
mock
Soft agar assay
RWPE-1 cells
mockTRAP1
TRAP1
GAPDH
kDa
75
36
A
         
Soft agar assay
RWPE-2 cells
co
lo
ny
 a
re
a 
(a
.u
.)
1.0
2.0
3.0
4.0
mock shTRAP1a shTRAP1b
B
75
36
kDa s
hT
RA
P1
a
sh
TR
AP
1b
mo
ck
TRAP1
GAPDH
             
D
3.0
6.0
9.0
Soft agar assay
MEF cells
co
lo
ny
 a
re
a 
(a
.u
.)
ΔNTRAP1TRAP1 mock
TR
AP
1
ΔNT
RA
P1
mo
ck
TRAP1
actin
75
42
kDa
            
Soft agar assay
SAOS-2 cells
E
co
lo
ny
 a
re
a 
(a
.u
.)
shTRAP1 ΔNTRAP1
3.0
6.0
9.0
12.0
15.0
mock
sh
TRAP1
ΔN
TRAP1mock
TRAP1
GAPDH
75
36
kDa
 
Figure 15. Figure 2. Mitochondrial TRAP1 confers transforming potential to cells. (A) Soft agar tumorigenesis assays were 
performed both in non-transformed cells, i.e. human epithelial prostate RWPE-1 cells and mouse embryo fibroblasts (MEF; D), stably 
transfected with either a TRAP1 cDNA or with a scrambled shRNA (mock); and in transformed cells, i.e. human epithelial prostate 
RWPE-2 cells obtained by v-Ki-Ras expression in RWPE-1 cells (B) and human osteosarcoma SAOS-2 cells (E) stably transfected with 
either a scrambled shRNA (mock) or with TRAP1 shRNAs (shTRAP1). Growth of colonies in soft agar was also assessed in MEF cells 
(D) or in SAOS-2 shTRAP1 cells (E) stably transfected with a TRAP1 construct lacking the mitochondrial import sequence (ΔNTRAP1). 
All along the Figure, Western immunoblots show TRAP1 expression levels in the different cell types; GAPDH or actin are shown as 
loading controls. Data are reported as mean±SD values (n≥3). 
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While when we down-regulate TRAP1 expression in RWPE-2 prostate cells, which are transformed by 
expression of v-Ki-Ras in RWPE-1 cells (Rasola et al., 2010a), abolished their tumorigenic features 
(Fig. 15). Mitochondrial localization of TRAP1 was essential for its pro-neoplastic activity, as 
expression of a TRAP1 construct devoid of its mitochondrial targeting sequence was not tumorigenic 
either in cancer or in non-transformed cells (Fig. 15).  
 
3.2 TRAP1 binds SDH and inhibits its succinate:coenzyme Q reductase (SQR) enzymatic activity 
We then asked whether TRAP1 promotes transformation by acting on mitochondrial metabolism, thus 
contributing to the Warburg phenotype. This could occur through an inhibitory effect on respiration. 
We observed that TRAP1 interacts with ETC complex IV (Figure 16A), but without affecting its 
cytochrome oxidase enzymatic activity (Figure 16C).  
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Figure 16. TRAP1 interacts with Complex IV of the respiratory chain complexes but it does not affects its activity. (A) TRAP1 
interacts with subunit COXII of Complex IV. This interaction is seen with a blue native gel and then the bands of the BNG were cut and 
loaded into a second dimension. (C) TRAP1 does not influences CIV activity. Complex IV activity was measured with a 
spectrophotometric assay. 
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TRAP1 also associated with ETC complex II, which couples the Krebs cycle to oxidative 
phosphorylation (OXPHOS) by oxidizing succinate to fumarate and then transferring electrons to 
coenzyme Q; hence, the enzyme is called either succinate dehydrogenase (SDH) or 
succinate:coenzyme Q reductase (SQR;  Cecchini, 2003; Lemarie and Grimm, 2011). We found that 
TRAP1 interacts with SDH (Fig. 17), using different approaches. We performed a Blue Native Gel 
(Fig. 15 A) and we cut the bands corresponding to Complex II and we loaded them into a normal  
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Figure 17. TRAP1 binds ETC complex II. (A) Blue native gel electrophoresis. Bands corresponding to complex II were cut, run on a 
SDS PAGE and probed with an anti TRAP1 and with an anti SDHB antibody. (B) SDS PAGE on whole Blue Native Gel was performed 
and TRAP1 interactions with Complex II and Complex IV were confirmed. (C) Crosslinking experiments on mitochondria from mock 
SAOS-2 cells. TRAP1 was immunoprecipitated after mitochondrial treatment with the crosslinker DTBP, loaded in parallel on separate 
lanes of a SDS-PAGE and probed with either an anti TRAP1 or with an anti SDHA antibody. (D) Complex II and TRAP1 
immunoprecipitations (IP) on lysates of SAOS-2 mock cells. The interaction between TRAP1 and SDHA is shown by co-IP. IgG are used 
in negative isotype controls.  
 
sodium dodecyl sulphate poliacrilamide gel (SDS-PAGE) and we found that TRAP1 interacts also with 
subunit B of Succinate dehydrogenase. To confirm that TRAP1 interacts only with Complex II and 
Complex IV of the respiratory chain complexes, we performed a SDS-PAGE on the whole Blue Native 
Gel and again we confirm that TRAP1 interacts only with Complex II and Complex IV of the 
respiratory chain complexes. There is also a possibility that TRAP1 interacts with Complex I, but it’s 
not so clear from the experiments performed so far. 
So we found an interaction between TRAP1 and Complex II and we decided to investigate if this 
interaction has also a functional meaning, so we measured Complex II activity (SQR activity). We 
found that the SQR enzymatic activity was increased in mitochondria from shTRAP1 cells relative to 
those derived from control cells (Fig. 18). Complex II activity was measured with a spectrophotometric 
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assay, using isolated mitochondria. shTRAP cells have a complex II activity that is double compare to 
mocks cells. 
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Figure 18. Analysis of the succinate:coenzyme Q reductase (SQR) enzymatic activity of complex II in mitochondria from SAOS-2 
cells. Analysis is performed on mitochondria from cultured cells; Mock indicates SAOS-2 cells stably transfected with a scrambled 
shRNA; shTRAP1 indicates SAOS-2 cells stably transfected with a TRAP1 shRNA. Enzyme activity values are compared to those of 
SAOS-2 mock cells in culture. On the right there is a representative experiment and on the left there is mean of nine different 
experiments. 
17-allylamino-17-demethoxygeldanamycin (17-AAG), an inhibitor of TRAP1/Hsp90 ATPase activity 
(Felts et al., 2000) whose availability to mitochondria was recently shown in situ (Xie et al., 2011), 
specifically increased SQR activity in control mitochondria, whereas shTRAP1 mitochondria were 
insensitive to the drug (Fig. 18). The effect of 17-AAG was unrelated to Hsp90, as Hsp90 protein levels 
were the same in mock and shTRAP1 cells (Fig 19). 
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Figure 19. Blot for Hsp90 levels. A western blot for the level of Hsp90 was performed in SAOS-2 cells. The levels of Hsp90 are the 
same for mock and shTRAP cells, so the effects of 17AAG is due to its action on TRAP1. 
 
The difference in Complex II activity between shTRAP cells and mock cells is real and it is not due to 
other factors. In fact there is no change in complex II protein levels (Fig. 20D) or in mitochondrial 
mass (Fig. 20E). The mitochondrial mass was measured with NAO staining, that binds to cardiolipin. 
In this way it is possible to have a measure of the mitochondrial mass in the cells. SAOS-2 cells have 
the same mitochondrial mass and also the same amount of Complex II. 
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Figure 20. No change in Complex II levels or mitochondrial mass. (D) Western immunoblot showing that no changes in SDHB 
protein expression occur during the focus forming assay (FF samples were obtained a the 15th experimental day). GAPDH is used as a 
loading control. (E) N-acrydine orange (NAO) cytofluorimetric analyses indicate that no change in mitochondrial mass occur between 
SAOS-2 mock and shTRAP1 cells. All along the Figure, bar graphs report mean±SD values (n≥3). Asterisks indicate a significant 
difference (p<0.01 with a Student's t test analysis). Cells are dubbed as in previous figures. 
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The experiments of Complex II activity were performed with mitochondria isolated from cells kept in 
culture, but we decided to investigate what happens during the focus forming, that is an in vitro 
tumorigenesis assay, that mimics tumor formation. We found that the SQR activity of ETC complex II 
was further inhibited in mitochondria from control cells that progressed through the focus forming 
assay, compared to mitochondria from the same cells kept in standard culture conditions, whereas no 
change in SQR activity could be appreciated in mitochondria from shTRAP1 cells during the focus 
forming experiments (Fig. 21).  
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Figure 21. Complex II activity during culture and during Focus forming. Activity values of mitochondria from cultured cells are 
compared with extracts from focus forming assays obtained at the 15th experimental day. Mock indicates SAOS-2 cells stably transfected 
with a scrambled shRNA; shTRAP1 indicates SAOS-2 cells stably transfected with a TRAP1 shRNA. Enzyme activity values are 
compared to those of SAOS-2 mock cells in culture. 
 
17-AAG could still reactivate the SDH enzyme in mitochondria of TRAP1-expressing cells undergoing 
the focus forming process (Fig. 21), indicating that even the enhanced inhibition of SQR activity 
occurring during the in vitro transformation progression is mediated by TRAP1 and remains reversible.  
In further accord with an inhibitory function of TRAP1 on ETC complex II, mitochondria from MEF 
cells stably expressing TRAP1 showed a diminished SQR activity compared to controls, and this 
inhibition was increased during the focus forming assay; 17-AAG reactivated SDH selectively in 
mitochondria from TRAP1-expressing MEFs (Fig. 22).  
48 
 
                                                             
 C
FF
assay
FF
assay
SQR activity
MEF mitochondria
mockTRAP1
C
om
pl
ex
 II
 a
ct
iv
ity
 ra
tio
2.5
0.5
1.0
1.5
2.0 *
*
*
*
17AAG
1 μM
17AAG
1 μM  
Figure 22. SQR activity is measured on mitochondria from mouse embryo fibroblasts (MEF) kept in culture or undergoing a 
focus forming assay (15th day). TRAP1 indicates cells stably transfected with the TRAP1-containing vector; cells stably transfected with 
a control vector are dubbed mock. Enzyme activity values are compared to those of mitochondria from TRAP1-expressing MEFs in 
culture. All along the Figure, the TRAP1 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) was added 5 min before starting 
recordings. Bar graphs report mean±SD values (n≥3); asterisks indicate significant differences (p<0.01 with a Student's t test analysis). 
 
3.3 TRAP1 induction inhibits complex II enzymatic activity in human colorectal cancers 
TRAP1 expression was shown to be increased in a variety of tumor types (Kang et al., 2007 and 
http://www.proteinatlas.org/). We compared the SQR activity of ETC complex II between colorectal 
cancers and the surrounding non-transformed mucosae obtained from a set of human patients. In all 
colorectal cancer samples at stage IV, characterized by metastases to lymph nodes and to distant sites, 
and in the majority of samples of stage I-III, characterized by absence of distant metastases, TRAP1 
was upregulated relative to normal mucosa, and this up-regulation was paralleled by a decrease in SQR 
activity, which could be partially rescued by 17-AAG (Fig. 23E). In a small subset of stage I-III 
colorectal cancers TRAP1 expression was not induced relative to surrounding non-tumor tissues. In 
these samples we could not detect any difference in SQR activity between samples from tumor and 
normal mucosa (Fig. 23F), strengthening the link between TRAP1 and the regulation of complex II 
activity. 
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Figure 23. Complex II enzymatic activity in human colorectal cancer samples. Representative analyses of SQR activity on human 
colorectal cancer (CRC) samples are carried out as in Figure 3E-F and compared to surrounding non-cancerous mucosae. As shown in the 
insets, samples reported in (E), which were obtained from metastatic CRC tumors, display an increase of TRAP1 expression in tumors 
with respect to mucosae; samples reported in (F), which were obtained from non-metastatic CRC tumors, do not show any increase of 
TRAP1 expression. GAPDH is shown as a loading control.  
3.4 TRAP1 inhibits cell oxygen consumption rate and ATP production by OXPHOS 
The SQR assays described so far measure the maximal enzymatic activity of complex II, as the 
complex is made accessible in permeabilized mitochondria and exposed to an excess of substrates. We 
next analyzed whether TRAP1 also affects the oxygen consumption rate (OCR) of living cells, in order 
to have a more physiological situation. We measured the oxygen consumption rate using the 
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Extracellular Flux Analyzer (Seahorse Bioscience), that allows to measure the oxygen consumption on 
adherent cells. Down-regulation of TRAP1 markedly increased mitochondrial-dependent respiration in 
SAOS-2 cells (Fig. 24). 
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Figure 24. Oxygen consumption rate are decreased by TRAP1 expression. Representative traces of oxygen consumption rate (OCR) 
experiments performed on monolayers of living SAOS-2 cells. Subsequent additions of the ATP synthase inhibitor oligomycin, of the 
uncoupler FCCP, of the ETC complex I inhibitor rotenone and of the ETC complex III inhibitor antimycin A were carried out.  
 
In shTRAP1 cells the extra OCR was used to make ATP, as it was inhibited by the ATP synthase 
blocker oligomycin; moreover, addition of the uncoupler FCCP increased respiration well above the 
basal level, indicating an increased respiratory capacity that remained fully sensitive to ETC inhibition 
by rotenone (Fig. 24). The comparison with control cells is striking, because unlike shTRAP1 cells they 
already utilize their maximal respiratory capacity under basal conditions, as shown by the lack of OCR 
increase with FCCP (Fig. 24), an arrangement implying that any additional ATP requirement must be 
provided by glycolysis.  
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The down-modulation of cell respiration by TRAP1 is a general phenomenon, because in all cancer cell 
models we tested, we obtained the same results (Fig. 25). We used as cell models: HeLa cells, MEF 
cells and RWPE-2 cells. 
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Figure 25. Oxygen consumption rate are decreased by TRAP1 expression in different tumor cell models. Representative traces of 
oxygen consumption rate (OCR) experiments performed on monolayers of living HeLa cells (A), or RWPE-2 cells (B), or MEFs (C). 
Subsequent additions of the ATP synthase inhibitor oligomycin, of the uncoupler FCCP, of the ETC complex I inhibitor rotenone and of 
the ETC complex III inhibitor antimycin A were carried out. 
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Moreover, expression of the TRAP1 cDNA in non-transformed fibroblasts markedly inhibited basal 
OCR, and abolished any respiratory reserve (Fig. 25C), mimicking the respiratory pattern of TRAP1-
expressing tumor cells. 
In full accord with the effect of the drug on SQR activity (see Fig. 21), the TRAP1 inhibitor 17-AAG 
increased OCR only in TRAP1-expressing cells (Fig. 26). 
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Figure 26. 17AAG is able to abolish the inhibitory effect of TRAP1 in basal respiration. The TRAP1 inhibitor 17-allylamino-17-
demethoxygeldanamycin (17-AAG) was added 30 min before starting experiments. Bar graphs report mean±SD values (n≥3); asterisks 
indicate significant differences (p<0.01 with a Student's t test analysis). 
 
Consistently we found that OXPHOS marginally contributes to ATP synthesis in mock cells, whereas a 
high proportion of the intracellular ATP content is provided by glycolysis, with a marked increase of 
glycolytic ATP during the in vitro tumorigenic process; instead, in shTRAP1 cells most of the ATP 
comes from OXPHOS (Fig. 27). 
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Figure 27. ATP levels were measured in mock (left) or in shTRAP1 (right) SAOS-2 cells. Cells are kept in standard culture 
conditions (bars on the left) or in a focus forming assay for 15 days (bars on the right). Where indicated, cells were treated for 2 hours 
with the ATP synthase inhibitor oligomycin or with the hexokinase inhibitor 5-thio-glucose (5TG) in a no glucose medium to 
discriminate between ATP produced by OXPHOS and by glycolysis. Bar graphs report mean±SD values (n≥3). 
 
3.5 SDH inhibitors selectively affect respiration, survival and soft agar growth in shTRAP1 cells 
A low concentration of the ETC complex II inhibitors 3-nitro-propionic acid (3-NP), which inactivates 
SDH after covalent binding with an Arg residue in the catalytic core of SDHA (Huang et al., 2006), or 
thenoyltrifluoroacetone (TTFA), which blocks electron transfer from succinate to coenzyme Q at the 
quinone-binding site in subunits B and D (Huang et al., 2006), inhibited OCR in shTRAP1 cells but 
were inactive in the presence of TRAP1 (Fig. 28), paralleling the down-modulation of the SQR activity 
induced by 3-NP only in TRAP1-expressing mitochondria (Fig. 28). 
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Figure 28. TRAP1-induced down-modulation of SDH activity decreases cell oxygen consumption rate Representative traces of 
oxygen consumption rate (OCR) experiments performed on monolayers of living SAOS-2 cells. Subsequent additions of the ATP 
synthase inhibitor oligomycin, of the uncoupler FCCP, of the ETC complex I inhibitor rotenone and of the ETC complex III inhibitor 
antimycin A were carried out. The SDH inhibitors 3-nitro propionic acid (3-NP; left) and thenoyltrifluoroacetone (TTFA; right) were 
added to cell monolayers 15 min before starting the experiments. (Bottom) Analysis of the effect of 3-NP on the succinate:coenzyme Q 
reductase (SQR) enzymatic activity of complex II in mitochondria from SAOS-2 cells. 3-NP was added 5 min before starting recordings; 
3-NP 10 mM was used to fully inhibit the SDH enzyme.  
 
These data indicate that TRAP1 limits maximal respiration by acting at ETC complex II. We also 
found that 3-NP inhibits in a dose-dependent fashion death in shTRAP1, but not in mock SAOS-2 cells 
placed in conditions of long-term starvation that mimic the paucity of nutrients found in the inner 
tumor mass during the phases of its rapid accrual (Fig. 29). Moreover, treatment with 3-NP partially 
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restored the ability of shTRAP1 cells to form colonies in soft agar, whereas it was ineffective on the 
colonies formed by control cells (Fig. 29). 
                     3NP
Vi
ab
le
 c
el
ls
 (%
)
100 μM 200 μM 500 μM
100
20
40
60
80
Serum depletion, 96h
SAOS-2 cells
shTRAP1mock
* *
                              
co
lo
ny
 a
re
a 
(fo
ld
 in
cr
ea
se
)
3-NP
100 μM
1
3
2
co
lo
ny
 a
re
a 
(fo
ld
 in
cr
ea
se
)
3-NP
100 μM
1
3
2
*
Soft agar assay
SAOS-2 cells
shTRAP1mock
 
Figure 29. TRAP1-induced down-modulation of SDH activity prompts resistance to stress stimuli. (Left) Cytofluorimetric cell death 
analysis of SAOS-2 cells starved in a medium without serum for 96 h with or without the reported concentrations of 3-NP. Viable cells 
are identified as double negative for propidium iodide and Annexin V–FITC. (Right) Soft agar assay on SAOS-2 cells. Data are reported 
as fold increase of colony area of mock cells grown with 3-NP compared with mock cells kept without the drug (left) and, separately, as 
fold increase of colony area of shTRAP1 cells grown with 3-NP compared with shTRAP1 cells kept without the drug (right). All along 
the Figure, in SAOS-2 experiments mock indicates cells stably transfected with a scrambled shRNA; shTRAP1 indicates cells stably 
transfected with a TRAP1 shRNA. All bar graphs report mean±SD values (n≥3). Asterisks indicate a significant difference (p<0.01 with a 
Student's t test analysis). 
 
The use of 3 nitropropionic acid allows us to mimics the inhibitory effect of TRAP1 on Complex II, so 
we can conclude that TRAP1 and 3 nitropropionic acid share the same binding site on Complex II 
(presumably subunit A). Moreover, reproducing the inhibitory effect of TRAP1 on Complex II activity, 
we can partially restored the ability of shTRAP1 cells to form colonies in soft agar, suggesting that the 
inhibition of Complex II is important for tumorigenesis. 
 
3.6 TRAP1 induces succinate accumulation and HIF1α stabilization 
It was shown that succinate accumulation induces HIF1 by inhibiting PHDs, the enzymes that 
hydroxylate HIF1α allowing its subsequent ubiquitin-dependent degradation (Selak et al., 2005). We 
observed that during the focus forming assay, the in vitro tumorigenesis assay that mimics tumor 
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formation, the intracellular level of succinate increased only in TRAP1-expressing cells (Fig. 30), 
matching the down-modulation of their SDH enzymatic activity (Fig. 21). 
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Figure 30. TRAP1 induces succinate accumulation. Bar graphs showing LC-MS measurements of intracellular succinate level. Values 
are compared with cultured mock SAOS-2 cells. 
 
We decided to investigate if succinate accumulation corresponds to HIF stabilization. In keeping with 
the succinate results, during the focus forming process HIF1α was detectable exclusively in TRAP1-
expressing cells (Fig. 31) and not in other conditions. 
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Figure 31. TRAP1 induces stabilization of HIF1α. Western immunoblot showing HIF1α expression in cultured cells and on extracts 
from focus forming assays obtained a the 15th experimental day. CoCl2 is used as a positive control for HIF1α stabilization. Blots were 
probed with an anti-actin antibody to check for protein load. 
 
We confirmed that HIF1α is not degraded in mock cells during focus forming experiment. In fact, 
HIF1α is hydroxilated (at the level of Pro402 and Pro564) in shTRAP cells, both in basal condition or 
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during the focus forming. In mock cells, HIF1α is hydroxilated only in basal condition and not during 
focus forming (Fig. 32). HIF1α hydroxilation by PHD2  is followed by proteasomal degradation. 
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Figure 32. Hydroxilation of HIF1α in SAOS-2 cells in basal condition and in focus forming. Western immunoblot showing HIF1α 
hydroxylation in cultured cells and on extracts from focus forming assays obtained a the 15th experimental day. CoCl2 is used as a positive 
control. Blots were probed with an anti-GAPDH antibody to check for protein load. 
 
We exclude the involvement of HIF2α in our model, in fact we do not see his stabilization during the 
focus forming experiment (Fig 33). 
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Figure 33. TRAP1 does not induce stabilization of HIF2α. Western immunoblot showing HIF2α expression in cultured cells and on 
extracts from focus forming assays obtained a the 15th experimental day. CoCl2 is used as a positive control for HIF2α stabilization. Blots 
were probed with an anti-actin antibody to check for protein load. 
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HIF1a can be stabilized or by the increase in succinate levels (Selak et al., 2005) or by hypoxia (Ishii et 
al, 2005). To verify what happens during focus forming in mock cells, we used pimonidazole 
(Hypoxyprobe-1). Pimonidazole hydrochloride is reductively activated in hypoxic cells and forms 
stable adducts with thiol (sulphydryl) groups in proteins, peptides and amino acids. MAb1 antibody 
binds to these adducts allowing their detection by immunochemical means. We performed again a 
focus forming with preincubation of pimonidazole and then performed a western blot (Fig. 34). We 
found that there is not hypoxia during focus forming assay, so HIF1α is effectively stabilized by the 
increase in succinate levels. 
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Figure 34. Pimonidazole-protein adducts. Pimonidazole (200μM) was added during the focus forming for 2 hours and then the cells 
were lysated. Cells kept for 24 hours in hypoxic chamber and treated in the same way with pimonidazole are used as positive control. 
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Consistently, in tumor samples obtained from nude mice xenografted with TRAP1-expressing SAOS-2 
cells (see Fig. 14), which were characterized by densely packed cells amidst which fibrotic and necrotic 
areas could be observed (marked as F and N, respectively, in the panels of Fig. 35), HIF1α was clearly 
detected in the majority of cells, the signal being particularly strong in the nuclei of cells where 
proliferation markers were also evident (compare the MIB/Ki67 and the HIF1α staining in Fig. 35). In 
these samples, cells displayed a punctuate TRAP1 signal that well fits with its mitochondrial 
localization (see the high magnification TRAP1 staining in Fig. 35). 
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Figure 35. Immunohistochemical inspections of tumors formed by SAOS-2 control cells after injection in nude mice (see Figure 
14). Hematoxylin/eosin and Azan/Mallory staining reveal tumors rich of densely packed cells, with few fibrotic areas (F) and a large 
number of necrotic regions (N). TRAP1 is visible in most cells (see the 6.25x magnification) as a punctuate signal (100x magnification), 
which is compatible with its mitochondrial localization. HIF1α expression is evident all along the samples (see the 6.25x magnification), 
mainly in the nuclear compartment of cells (100x magnification), and the signal is particularly strong in the perinecrotic areas, where also 
the proliferation marker MIB-1/Ki67 is found (25x magnifications). 
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3.7 TRAP1 induces succinate accumulation and HIF1α stabilization, which is required for tumor 
cell growth 
We found that dimethyl succinate induce the stabilization of HIF1α, without any differences between 
shTRAP cells and mock cells, both in basal or during focus forming (Fig. 2A). Moreover, the addition 
of dimethyl succinate induce colonies formation in soft agar assay only in shTRAP cells and not in 
other condition. So the increase in cytosolic succinate in our model is responsible for colonies 
formation (Fig.2B). 
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Figure 36. Dimethylsuccinate induces HIF1α stabilization and growth of colonies in soft agar assay. In (A) dimethyl succinate 
20mM was added for 48 h and then cells were lisated for western blot analysis. Clorure Cobalte is used as positive control. In (B) 
dimethyl succinate 5mM was added all along the soft agar assay. 
 
HIF1α inhibition with a cell-permeable esterified form of α-ketoglutarate (1-trifluoromethyl benzyl-α-
ketoglutarate, TaKG), which reverses HIF1α stabilization by restoring PHDs enzymatic activity 
(MacKenzie et al., 2007; Tennant et al., 2009) fully abolished formation of foci in TRAP1-expressing 
tumor cells (left) and in MEFs transfected with a TRAP1 cDNA (right). In fact this compound compete 
with succinate for the binding site on PHDs, so these enzymes are activated and they induce HIF1α 
degradation (Fig. 37). 
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Figure 37. Focus forming assay on SAOS-2 cells or MEFs grown with or without 1-trifluoromethyl benzyl-α-ketoglutarate 
(TaKG). This compound was added during all along the experiment of focus forming. All along the Figure, bar graphs report mean±SD 
values (n≥3). Asterisks indicate a significant difference (p<0.01 with a Student's t test analysis). Cells are dubbed as in previous figures. 
 
We tried to establish the importance of HIF1α stabilization not only with a chemical approach, but also 
with short hairpin RNAs. We performed interference on HIF1α (Fig. 38, left) or on HIF1β (Fig. 38, 
right), using different short hairpin RNAs. In both cases, we fully abolished formation of foci in 
TRAP1-expressing tumor cells. 
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Figure 38. Focus forming assay on SAOS-2 cells where HIF1α (left) and HIF1β (right) expression had been knocked-down by 
RNA interference. In the inset the maximal HIF1α expression is reported after CoCl2 treatment. All along the Figure, bar graphs report 
mean±SD values (n≥3).  
 
These last experiments show the importance of HIF1a for our cell models. In fact when HIF is not 
stabilized, we do not observe in vitro tumorigenesis. 
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4. Discussion 
 
Tumor cells tend to increase their glycolytic activity without a matching increase of oxidative 
phosphorylation (Warburg, 1927; Warburg, 1956). Inhibition of the tumor suppressor p53 or 
activation of the transcription factor HIF1 curtail OXPHOS by inducing the autophagic 
degradation of respiratory complexes and by abrogating the synthesis of some of their 
subunits (such as SDHB) or assembly factors (Denko, 2008; Semenza, 2010; Vousden, 
2009). Conversely, OXPHOS inhibition can play a causal role in tumorigenesis. Inactivating 
mutations in mtDNA genes encoding for subunits of ETC complex I and III were found 
associated with renal oncocytomas (Gasparre, 2008), as well as thyroid and prostate cancers 
(Abu-Amero, 2005; Petros, 2005). However, these mutations are confined to a small set of 
neoplasms, and the lack of clear-cut molecular mechanisms hampers the definition of 
whether OXPHOS inhibition as such can play a general tumorigenic role. Key findings of the 
present work are the demonstration that the mitochondrial chaperone TRAP1, which is 
widely expressed in tumors, but not in highly proliferating, non-transformed cells 
(http://www.proteinatlas.org/), is a component of the molecular machinery that decreases 
mitochondrial respiration; and that this event is crucial for neoplastic progression. Indeed, we 
find that TRAP1 behaves as an oncogene, since (i) without TRAP1 tumorigenesis is blunted 
both in vitro and in vivo; and (ii) TRAP1 expression confers tumorigenic potential to non-
transformed cells. We observe that TRAP1-mediated inhibition of SDH limits the maximal 
rate of respiration and leads to succinate accumulation, followed by HIF1α stabilization. 
HIF1 induction elicits a pseudohypoxic response which can boost neoplasm evolution 
promoting angiogenesis, epithelial/mesenchymal transition and the glycolytic switch 
(Brahimi-Horn, 2011; Semenza, 2010) accordingly, we observe that promoting HIF1α 
degradation abolishes the neoplastic potential of TRAP1-expressing cells. In our model, 
HIF1α stabilization emerges after several days of in vitro transformation, when SDH is more 
strongly inhibited by TRAP1. This suggests that a threshold SDH inhibition must be reached 
to allow for succinate accumulation, which is not at all surprising given the multiple 
pathways through which excess succinate can be utilized including increased heme synthesis 
(Frezza, 2011). Despite a partial respiratory inhibition, TRAP1-expressing cells fully utilize 
their residual respiratory capacity to produce ATP, as shown by OCR experiments, but 
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reorient their metabolism towards glycolysis to meet any energy demand that exceeds 
respiratory capacity, in complete accord with Warburg’s observations. 
TRAP1 is likely to begin a feed-forward loop, as it inhibits SDH and respiration (hence 
OXPHOS) and induces HIF1, which in turn further inhibits OXPHOS (Denko, 2008; 
Semenza, 2010) and directly down-regulates SDH by induction of miR-210 (Puissegur, 
2011). The complete block of the SDH enzyme caused by loss-of-function mutations would 
be an extreme case only seen in  specific subsets of tumors (Bardella, 2011); whereas the 
partial and reversible SDH inhibition caused by TRAP1 and its increased expression levels , 
would mediate a general pro-neoplastic function of TRAP1, which fits its identification as a 
bona fide hypoxia- and c-Myc-inducible gene (Coller, 2000; Ruiz-Romero, 2010). 
Tumor cells could be endowed with a multi-chaperone mitochondrial complex, as TRAP1 
interacts with cyclophilin D, Hsp90 and Hsp60 (Ghosh, 2010; Kang, 2009). Notably, TRAP1 
is involved in the inhibition of the mitochondrial permeability transition pore (Kang, 2007), 
whose opening irreversibly commits cells to death (Rasola, 2007; Rasola, 2010), and we have 
observed that keeping the pore locked can be used by tumor cells to evade apoptosis (Rasola, 
2010). Thus, TRAP1 could take part in several mitochondrial changes that crucially 
contribute to the neoplastic phenotype. Targeting its chaperone activity and molecular 
interactors could dismantle the metabolic and survival adaptations of neoplastic cells, paving 
the way to the development of highly selective mitochondriotropic anti-neoplastic drugs. 
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